App, Platform, Data, AI: The Four Pillars of Modern Healthcare Technology Infrastructure The evolution of healthcare technology has reached a critical juncture where the traditional, fragmented approach to digital health is being superseded by an integrated, four-pillar architectural framework. This modern infrastructure is characterised by an interlocking relationship between the user-facing Application, the service-orchestrating Platform, the governed Data layer and the value-driving Artificial Intelligence (AI) models that sit atop the stack. For enterprises seeking to build scalable, sustainable and defendable businesses, this configuration represents the fundamental blueprint for success in a landscape increasingly defined by value-based care, precision medicine, and the demand for clinician-centric design. The Application Pillar: Interface Design and Human-Centred Clinical Engagement The application layer serves as the primary interface through which the broader technological ecosystem interacts with its human constituents, specifically clinicians and patients. In the context of a sustainable healthcare technology business, the application is no longer a standalone tool but a sophisticated conduit for workflow orchestration and behavioral engagement. For clinicians, the application must resolve the persistent friction between administrative documentation and direct patient care, while for patients, it must facilitate a transition from passive recipients of care to active participants in health management. Clinician-Facing Applications and the Architecture of Usability The modern clinician lives within the Electronic Health Record (EHR), and any application that forces a departure from this primary environment faces significant adoption barriers. Consequently, the architecture of successful clinician-facing apps is increasingly "embedded" or "context-aware". By utilising standards such as SMART on FHIR, these applications appear as integrated components of the clinical workspace, pulling relevant data automatically and eliminating the need for redundant logins or manual data re-entry. The concept of "intuitive design" has shifted from a mere preference to a strategic necessity. The next generation of healthcare providers expects consumer-grade experiences, and tools that require extensive onboarding or manuals are considered failures in the modern architectural paradigm. One of the most critical metrics for these applications is the "two-click rule," which suggests that any AI-related task or critical data retrieval should require no more than two clicks to minimize cognitive load and maximise compliance. Feature Category Technical Implementation Clinical Impact Smart Defaults Automated pre-population of fields based on EHR data Reduction in documentation time and clerical errors Contextual Nudges Surfacing relevant evidence-based insights at the point of care Improved adherence to clinical guidelines and best practices Tiered Alerting Priority-based classification of clinical notifications Mitigation of alert fatigue and prioritization of critical events Secure Communication End-to-end encrypted role-based messaging channels Enhanced care team coordination and data privacy Patient Engagement and the Shift to Longitudinal Self-Management Patient-facing applications in a sustainable infrastructure are designed to foster long-term engagement rather than episodic interaction. This is achieved through hyper-personalisation, where the application uses clinical data, social determinants of health (SDOH) and behavioural patterns to tailor interventions. For instance, a patient with a chronic condition like diabetes may receive reminders, educational modules and health trackers that are specifically calibrated to their literacy level and cultural context. Engagement is further driven by "Shared Decision-Making" (SDM) modules, where applications provide decision aids, such as visual charts or interactive videos, to help patients understand their treatment options. This creates a sense of ownership over the care plan, which significantly improves treatment adherence and outcomes. The Platform Pillar: Orchestration and the Modularisation of Healthcare Services The platform layer is the "operating system" of the healthcare technology stack, acting as the foundation that connects diverse tools, data flows and user types into a cohesive ecosystem. While an application handles a specific task, the platform orchestrates the underlying services, such as billing, scheduling, and clinical decision support, to ensure they work in harmony. Architectural Patterns for Scalable Infrastructure A scalable HealthTech business must choose an architectural pattern that supports growth without requiring a total system overhaul. Three patterns have emerged as the standard for modern platforms: Microservices, Event-Driven Architecture, and Multi-Tenant SaaS. Microservices : This pattern breaks down a complex platform into small, independent services that perform specific tasks. This allows for "independent scalability," where a high volume of traffic in the scheduling service does not degrade the performance of the billing or clinical records services. Event-Driven Architecture : This model is essential for real-time responsiveness, particularly in remote patient monitoring (RPM). It operates through "events", such as a sensor flagging an irregular heartbeat, which then trigger a cascade of reactions, including pings to the care team and automated logging in the patient's record. Multi-Tenant SaaS : For B2B platforms selling to clinics or hospitals, a multi-tenant architecture is the most efficient model. It allows a single instance of the software to serve multiple organizations (tenants) while ensuring "rock-solid" data isolation and security. The Evolution from Un-bundling to Re-bundling The healthcare platform market is currently experiencing a shift from "un-bundling", where point solutions were built for every individual task—to "re-bundling," where integrated platforms act as hubs for multiple services. These platforms create a "flywheel effect" by becoming more valuable with every new connection and service they orchestrate. They serve as ecosystems that coordinate developers, device makers, and clinical providers, enabling a seamless flow of value across the entire healthcare continuum. Aspect Individual Application End-to-End Platform Core Purpose Handles one specific task (e.g., booking) Acts as a base for multiple workflows and teams Flexibility Rigid structure with limited room for change Modular setup allowing for new feature additions Data Movement Siloed data within its own logic Standards-based connection (FHIR/OpenEHR) Scalability Profile Limited to the specific use case Independently scalable services The Data Pillar: Governance, Integrity, and the Interoperability Mandate Data is the lifeblood of modern healthcare technology, but its value is often locked away in silos or compromised by poor quality and inconsistent governance. A sustainable technology infrastructure treats data as a strategic asset, implementing robust layers for ingestion, transformation and governance. The Challenge of Healthcare Data Silos Despite decades of investment, data silos remain a persistent barrier to innovation. Legacy systems, proprietary formats, and cultural resistance often prevent the free flow of information between payers, providers, and patients. Breaking down these silos requires a combination of technological standards and shared governance frameworks. Recent progress is notable: approximately 70% of U.S. hospitals now engage in four domains of interoperable data exchange, up significantly from previous years. The Medallion Architecture and Data Quality To ensure that data is "AI-ready," many organisations are adopting the "medallion architecture," which categorises data based on its state of refinement: Bronze Layer : Raw, unprocessed data from disparate sources (EHRs, labs, devices). Silver Layer : Data that has been cleaned, deduplicated, and validated through ETL (Extract, Transform, Load) processes. Gold Layer : Aggregated and analysed data that is ready for consumption by AI models or business intelligence tools. Quality in this context is not just about error correction but also about "bias awareness" and "contextual integrity". For example, if a dataset over-samples one demographic, an AI model trained on it will likely reproduce those biases, leading to inequitable care. Interoperability Standards: FHIR and OpenEHR The move toward "liquid data" is facilitated by global standards that allow different systems to speak the same language. HL7 FHIR : Fast Healthcare Interoperability Resources has become the global standard for real-time health data exchange, utilised for its vendor-neutral format and web-based APIs. OpenEHR : More common in Europe, this standard is used for rich, long-term clinical records and semantic interoperability. Interoperability is not just a technical requirement but a strategic one; the most successful platforms are those that move from simply "storing" data to "orchestrating" it in real time across a global ecosystem. The AI Pillar: Driving Clinical and Operational Value through Intelligence AI represents the "intelligence layer" that sits atop the application, platform, and data pillars to drive tangible value. In a modern healthcare technology business, AI is moving from a "passive observer" to an "active operator," capable of identifying risks, automating workflows, and personalising treatment plans at scale. Clinical Decision Support and Predictive Analytics AI models are delivering a significant competitive advantage by streamlining research and providing superior accuracy in diagnostics. By analysing millions of records, AI can identify "care gaps", such as a patient missing a critical screening or being eligible for a clinical trial and flag them directly within the clinical workflow. For instance, AI-driven sepsis detection systems, when integrated smoothly into the EHR, have demonstrated the ability to reduce treatment errors by providing actionable, real-time alerts to care teams. The Role of Large Language Models (LLMs) and Generative AI The integration of LLMs into healthcare is transforming how clinicians interact with information. Stanford’s "ChatEHR" platform illustrates a modern approach, where a "self-hosted gateway" securely connects cutting-edge AI capabilities to the EHR, translating technical FHIR data into clinician friendly structures like treatment plans and episodes of care. To build trust in these clinical GenAI solutions, four pillars of trust are essential: Rigorous Clinical Review : Expert oversight of AI-generated answers to ensure reliability. Real-World Application : Testing in actual clinical settings to evaluate contextually appropriate responses. Curated, Evidence-Based Sources : Utilising trusted medical literature rather than ungoverned open-source data. Continuous Model Improvements : Implementing feedback loops from early adopters to fine-tune algorithms. Evaluating Medical AI: The MedHELM Framework As AI becomes central to care delivery, robust evaluation frameworks are required to ensure safety and efficacy. The MedHELM (Holistic Evaluation of Large Language Models for Medical Applications) framework is a specialised benchmarking system that evaluates LLMs across 121 medical tasks grouped into categories such as Clinical Decision Support, Administration and Patient Communication. This framework ensures that AI performance is measured against real-world healthcare needs rather than just standardised medical exams. AI Capability Mechanism of Value Outcome Goal Predictive Risk Scoring Combining SDOH and clinical data to build risk profiles Reduced avoidable admissions and better value-based care Workflow Automation Automating administrative tasks like claims and billing Reduced manual workload and accelerated reimbursement Information Retrieval Analyzing large volumes of clinical records for rapid insights Enhanced clinician efficiency and diagnostic speed Personalization Engines Adaptive interfaces and tailored care plans Improved patient engagement and adherence Economic Moats and the "Defendability" of HealthTech Businesses A scalable and sustainable healthcare technology business is not only built on its four architectural pillars but also on its ability to create competitive "moats" that protect it from incumbents and emerging rivals. These moats are often generated by the interaction between the pillars themselves. The Data Flywheel and Defensibility The "data flywheel" is a powerful moat where a company's data assets continuously improve its product, attracting more users and generating even more data. Tempus AI provides a clear example of this mechanism: Generate : Their genomics lab sequences oncology samples, creating new molecular data. Ingest : This data is added to their proprietary database of 45 Million patient records. Insight : The increasing volume of data makes their AI models smarter, providing better clinical insights. Scale : Better insights lead to more physicians ordering tests, thus completing the cycle. Switching Costs and Network Effects High switching costs and network effects are standard moats for enterprise healthcare software. Switching Costs : Once a platform like Epic is deeply integrated into a hospital’s clinical and financial workflows, the cost and disruption of switching to a competitor become nearly insurmountable. Network Effects : Platforms become more valuable as more participants join. A telehealth platform with more doctors is more attractive to patients, which in turn attracts more doctors. Vertical AI and Domain Specific Data Moats In the current market, "Vertical AI" companies (those focused on specific industries like oncology, legal, or life sciences) are outperforming horizontal players. Veeva Systems, for example, has built a "Sweet Spot" position by layering AI across a deeply integrated stack of clinical trial management and CRM tools, backed by a domain-specific data moat that horizontal players like Salesforce cannot easily replicate. App, Platform, Data, AI: The Four Pillars of Modern Healthcare Technology Infrastructure Global Implementation: Navigating the US and UK HealthTech Landscapes The path to building a sustainable HealthTech business varies significantly depending on the regulatory and payment structures of the target market. The UK's NHS: A Unified Dataset with Bureaucratic Barriers The UK’s National Health Service (NHS) represents a unique "asset for AI", a theoretically unified dataset for a population of 60 million people. However, the UK market is characterised by several implementation hurdles: Procurement Complexity : The NHS procurement system is often described as overly complex and bureaucratic, with requirements that can deter smaller startups from bidding on contracts. Regulatory Uncertainty : Since Brexit, regulatory uncertainty and the delay in approving new medical devices have shifted some investment toward the US market. Data Rights : In the UK, patients have strong rights over their data, and suppliers generally do not own the information, which differs from the more permissive US model. The US Market: Fragmentation and Commercial Flexibility The US healthcare system is highly fragmented across thousands of payers and providers, creating a different set of challenges and opportunities. Flexible Data Environment : The US offers a more permissive environment for selling and distributing de-identified data (subject to consent), which fuels the growth of "TechBio" companies like Tempus and Flatiron Health. Complex Billing Infrastructure : The sheer volume of payers in the US has fostered a robust software industry dedicated to intricate billing, payment reconciliation, and fraud detection. Market Factor United Kingdom (NHS) United States (Multiple Payers) Data Governance GDPR / MHRA Guidelines HIPAA / Cures Act Market Structure Centralized procurement, finite size Fragmented silos, high flexibility Data Ownership Patient-centric, supplier doesn't own Permissive; high secondary use potential Innovation Drivers AI, genomics, and population health RCM, billing, and clinical efficiency Barriers to Sustainable Healthcare Technology Transformation Despite the clear blueprint provided by the four-pillar infrastructure, several barriers prevent organisations from achieving full sustainability and scalability. Technical and Operational Challenges Many enterprises struggle with the transition from legacy monolithic systems to modern micro-capabilities. This "technical debt" can lead to inconsistent security policies and integration failures. Furthermore, the lack of "explainability" in deep learning models remains a major barrier to clinical adoption; if a clinician cannot trace the reasoning behind an AI prediction, they are unlikely to trust its output. Cultural and Workforce Barriers The success of any technology is ultimately dependent on the people who use it. Resistance to change, "blame cultures" in high-pressure environments, and insufficient funding for change management are significant barriers within the NHS and other large systems. Additionally, the "alert fatigue" phenomenon highlights the need for technology to adapt to clinicians rather than forcing clinicians to adapt to the technology. Future Outlook: The Rise of Agentic AI and Outcome-Based Models As the healthcare technology industry moves toward 2026 and beyond, several trends are poised to redefine the four-pillar architecture. From Copilots to Autonomous AI Agents While the current wave of AI focuses on "Copilots" that assist users, the next generation will be "Agentic AI", systems that autonomously execute multi-step workflows. For example, a CRM agent for healthcare might not just draft an email but research a patient's eligibility for a trial, contact the patient, and update the clinical record without human intervention.This shift will likely move SaaS pricing from "per-seat" to "outcome-based" or "usage-based" models. The Integration of Real-Time "T+0" Infrastructure The "modern data stack" is evolving to support real-time data streaming and inference, moving away from batch processing. This is particularly critical in Pharmacy Benefit Management (PBM) and Claims Adjudication, where architectures must ingest millions of clinical data points to automate decisions with near-zero latency. The Sustainability of the Healthcare Business Model The ultimate goal of the four-pillar infrastructure is to build a sustainable system that optimizes costs while improving quality of care and workforce well-being. By utilising interoperable platforms, AI-driven proactive care, and secure data layers, enterprises can transition from reactive treatment to high-performing, value-based care models. Conclusion: The Path Forward for HealthTech Architects The construction of a scalable, sustainable and defendable healthcare technology business requires a holistic commitment to all four interlocking pillars: App, Platform, Data, and AI. Success is no longer defined by the deployment of a single "killer app" but by the durability and fluidity of the entire ecosystem. As technology leaders transition to decentralised, AI-ready architectures, they must prioritise: Clinical Trust : Building systems that are transparent, evidence-based, and embedded in clinician workflows. Architectural Agility : Adopting domain-driven designs and micro services to allow for global flexibility and rapid innovation. Data Sovereignty : Implementing robust governance and standards-based interoperability to turn raw information into strategic intelligence. Economic Defensibility : Leveraging data flywheels and network effects to create long-term value and competitive moats. The integration of these foundations creates the conditions where innovation moves beyond pilots to scalable implementation, ultimately delivering faster, safer, and more affordable outcomes for patients globally. The legacy of the modern HealthTech architect will not be found in specific lines of code, but in the resilience and impact of the digital ecosystems they build to support the future of human health. Nelson Advisors > European MedTech and HealthTech Investment Banking   Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk Nelson Advisors regularly publish Thought Leadership articles covering market insights, trends, analysis & predictions @  https://www.healthcare.digital     Nelson Advisors publish Europe’s leading HealthTech and MedTech M&A Newsletter every week, subscribe today!  https://lnkd.in/e5hTp_xb    Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk #NelsonAdvisors   #HealthTech   #DigitalHealth   #HealthIT   #Cybersecurity   #HealthcareAI   #ConsumerHealthTech   #Mergers   #Acquisitions   #Partnerships   #Growth   #Strategy   #NHS   #UK   #Europe   #USA   #VentureCapital   #PrivateEquity   #Founders   #SeriesA   #SeriesB   #Founders   #SellSide   #TechAssets   #Fundraising   #BuildBuyPartner   #GoToMarket   #PharmaTech   #BioTech   #Genomics   #MedTech Nelson Advisors LLP   Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Nelson Advisors @ 2026 Events   Digital Health Rewired > March 2026 > Birmingham, UK    NHS ConfedExpo   >  June 2026 > Manchester, UK    HLTH Europe >  June 2026, Amsterdam, Netherlands   HIMSS AI in Healthcare  >  July 2026, New York, USA   Bits & Pretzels >  September 2026, Munich, Germany     World Health Summit 2026  >  October 2026, Berlin, Germany   HealthInvestor Healthcare Summit >  October 2026, London, UK  HLTH USA 2026 >  October 2026, USA   Barclays Health Elevate >  October 2026, London, UK    Web Summit 2026 >  November 2026, Lisbon, Portugal     MEDICA 2026 >  November 2026, Düsseldorf, Germany   Venture Capital World Summit > December 2026 Toronto, Canada Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk

Nelson Advisors invited to Judge and Mentor the QSTP x Merck FemTech Accelerator 2026 Nelson Advisors invited to Mentor and Judge the QSTP x Merck FemTech Accelerator 2026 https://nelsonadvisors.co.uk/blog/nelson-advisors-invited-to-mentor-and-judge-the--qstp-x-merck-femtech-accelerator-2026 QSTP x Merck FemTech Accelerator 2026 Qatar Science & Technology Park (QSTP), a member of Qatar Foundation, in partnership with Merck, a leading science and technology company, announced the launch of the QSTP x Merck FemTech Accelerator, a dedicated accelerator designed to support deep tech and impact driven FemTech startups addressing critical unmet needs in women’s health and transforming health outcomes for women across the MENA region. The program will identify and support up to 30 leading FemTech startups developing breakthrough solutions across key women’s health domains, focusing on innovations powered by artificial intelligence, robotics, and materials science. Selected companies will receive access to advanced scaling support, market entry pathways, and clinically aligned pilot opportunities to support commercial expansion into Qatar, with pathways to scale across the wider region. Beyond supporting individual startups, the initiative is designed to generate and track measurable impact at scale, aligned with Qatar Foundation’s mission to improve women’s health outcomes across the region. Through a multi-country approach, the QSTP x Merck FemTech Accelerator will enable deep-tech startups to be piloted, validated, and adopted across multiple markets, addressing women’s health challenges at both regional and global levels. Leveraging QSTP’s innovation ecosystem and Merck’s global scientific and healthcare expertise, selected startups will benefit from curated mentorship, exposure to regional healthcare stakeholders, and opportunities to explore collaboration within Qatar’s health and research landscape. The accelerator will also facilitate engagement with relevant national institutions and ecosystem partners. Aligned with Qatar Foundation’s innovation and healthcare priorities, the accelerator aims to position the country as a regional and global hub for women’s health innovation, while addressing the urgent need for greater investment, research, and commercializ]ation in FemTech, one of the fastest-growing and most impactful sectors in global health technology. Source:  https://qstp.qa/programs/femtech/ Source:  https://qstp.qa/qstp-partners-with-merck-to-launch-femtech-accelerator-advancing-womens-health-innovation/ Nelson Advisors invited to Judge and Mentor the QSTP x Merck FemTech Accelerator 2026 Nelson Advisors > European MedTech and HealthTech Investment Banking   Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk Nelson Advisors regularly publish Thought Leadership articles covering market insights, trends, analysis & predictions @  https://www.healthcare.digital     Nelson Advisors publish Europe’s leading HealthTech and MedTech M&A Newsletter every week, subscribe today!  https://lnkd.in/e5hTp_xb    Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk #NelsonAdvisors   #HealthTech   #DigitalHealth   #HealthIT   #Cybersecurity   #HealthcareAI   #ConsumerHealthTech   #Mergers   #Acquisitions   #Partnerships   #Growth   #Strategy   #NHS   #UK   #Europe   #USA   #VentureCapital   #PrivateEquity   #Founders   #SeriesA   #SeriesB   #Founders   #SellSide   #TechAssets   #Fundraising   #BuildBuyPartner   #GoToMarket   #PharmaTech   #BioTech   #Genomics   #MedTech Nelson Advisors LLP   Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Nelson Advisors @ 2026 Events   Digital Health Rewired > March 2026 > Birmingham, UK    NHS ConfedExpo   >  June 2026 > Manchester, UK    HLTH Europe >  June 2026, Amsterdam, Netherlands   HIMSS AI in Healthcare  >  July 2026, New York, USA   Bits & Pretzels >  September 2026, Munich, Germany     World Health Summit 2026  >  October 2026, Berlin, Germany   HealthInvestor Healthcare Summit >  October 2026, London, UK  HLTH USA 2026 >  October 2026, USA   Barclays Health Elevate >  October 2026, London, UK    Web Summit 2026 >  November 2026, Lisbon, Portugal     MEDICA 2026 >  November 2026, Düsseldorf, Germany   Venture Capital World Summit > December 2026 Toronto, Canada Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk

This Week in European MedTech and HealthTech: 2nd April 2026 The final week of March and the beginning of April 2026 have been characterised by a shift toward industrial rigor and regulatory convergence. As the "Great Rationalisation" of European HealthTech continues, the focus has moved from experimental AI to clinical validation and sovereign cloud infrastructure. Here are the major developments in European HealthTech for the week of March 26 – April 2, 2026: 1. Major Product Launches & Sovereign Cloud Adoption BD (Becton, Dickinson and Company): On April 1, 2026, BD launched its Pyxis™ Pro medication dispensing system and Incada™ Connected Care platform in Europe. AWS European Sovereign Cloud: In a significant move for data privacy, BD announced it will host these solutions on the AWS European Sovereign Cloud. This allows EU healthcare providers to meet strict digital sovereignty requirements while maintaining the scale of global cloud infrastructure. 2. Regulatory & Policy Updates AI Act Integration: The European Commission updated its guidance on AI in Healthcare, focusing on aligning the new AI Act with existing MDR/IVDR (Medical Device/In Vitro Diagnostic Regulations). The goal is a "single sectoral route" for certification to prevent high-risk medical AI from needing double approval. MDR "Helsinki Procedure": New proposals are moving forward to codify the "Helsinki procedure," designed to ease bottlenecks for "borderline" products (those that sit between medical devices and other categories like cosmetics or supplements). EU HTA Machinery: The European Health Technology Assessment (HTA) framework is now fully live. Joint clinical assessments are ramping up, raising the bar for the evidence startups need to provide for pan-European market access. 3. Funding & Strategic Initiatives Digital Europe Programme: The EU announced a massive wave of new calls for proposals opening April 20, 2026. Key focus areas include: AI-based image screening in medical centers. Capacity building for the European Health Data Space (EHDS). Digital solutions for regulatory compliance through data. EIT Health: Launched its 2026 Innovation Validation Call, offering up to €850k (50% co-funded) for late-stage digital health projects that are ready for clinical validation and market launch. WHO & Digital Wallets: On March 23, the WHO and partners launched a new initiative to expand the use of digital health wallets, aimed at making personal health records more portable across borders. 4. Biotech & MedTech "Companies to Watch" Isomorphic Labs (UK): The Alphabet spin-off is reportedly preparing for its first human clinical trials using AI-designed small molecules, expected to begin later this year. Vandria (Switzerland): The clinical-stage biotech is gaining traction with its lead asset VNA-318, an oral small molecule targeting mitochondrial function for the treatment of Alzheimer's. CMR Surgical (UK): Its Versius Plus robotic platform has surpassed 40,000 procedures. The company is currently focused on its 2026 U.S. commercialisation push while expanding its digital analytics suite in Europe. To discuss how Nelson Advisors can help your HealthTech, MedTech, Health AI or Digital Health company, please email lloyd@nelsonadvisors.co.uk   >>>>    The week of March 30 – April 2, 2026, has seen European MedTech pivot toward digital integration, regulatory simplification, and green manufacturing. While the "Great Rationalisation" of post-pandemic funding continues, the focus has shifted to the mandatory adoption of central databases and the refinement of the MDR/IVDR frameworks. Here are the major developments in European MedTech this week: 1. Regulatory "Smarter Certification" & EUDAMED Deadlines European Commission Simplification: On March 31, the Commission advanced a draft regulation to simplify MDR/IVDR requirements. The most notable change is the removal of the rigid five-year certificate validity cap, moving instead toward a continuous, risk-based surveillance model. This is intended to reduce the administrative "bottleneck" that has plagued notified bodies. EUDAMED Countdown: The Commission confirmed that four key modules of the European Database on Medical Devices (EUDAMED) will become mandatory on May 28, 2026. This week, industry leaders issued a final call for firms to validate their device data, as transparency requirements will significantly increase litigation exposure and market visibility starting this summer. UK International Reliance: The MHRA (UK) launched a consultation (closing April 10, 2026) on the indefinite recognition of CE-marked devices in Great Britain. This marks a critical step in the UK's "International Reliance Framework," designed to streamline approvals for devices already cleared by the EU or US FDA. 2. Major Corporate & Clinical Moves BD (Becton, Dickinson and Company): Successfully launched its Pyxis™ Pro and Incada™ Connected Careplatforms in Europe on April 1. Crucially, BD is among the first major players to host these clinical systems on the AWS European Sovereign Cloud, addressing growing EU demands for data sovereignty and local processing. Mölnlycke Health Care: On March 31, the Swedish MedTech giant issued a "Call to Action" regarding the European chronic wound crisis, coinciding with their 2025 Annual Report. The report highlights their "ProcedurePak" trays hitting the 100 million unit milestone, signaling a heavy shift toward sustainable, pre-assembled surgical kits. Johnson & Johnson: Released one-year data (March 30) for ICOTYDE™, a first-in-class targeted oral peptide.While a pharmaceutical development, it is being paired with new digital adherence monitoring tools specifically designed for European market access. 3. Funding & Innovation Cycles EIC Pathfinder Awards: On April 1, 2026, the European Innovation Council (EIC) awarded €118 million to 30 breakthrough research projects. A significant portion of this funding is directed toward Biotechnology for healthy ageing and Modular Multi-robot platforms for surgical assistance. Horizon Europe (Health): New calls under the HORIZON-HLTH-2026 program are now open for submission.Key areas of interest for MedTech include: Regulatory science to support patient-centred technology. New Approach Methodologies (NAMs) to replace animal testing in medical device validation. Scaling innovation in cardiovascular health, specifically targeting AI-based diagnostic wearables. 4. Sustainability & Circular Economy Circular Economy Act: A coalition of 65 associations, led by MedTech Europe, issued a joint statement this week pushing for harmonized rules in the upcoming Circular Economy Act. The industry is advocating for a "Single Market, Single Rules" approach to allow for the legal refurbishment and recycling of high-value medical components across EU borders. To discuss how Nelson Advisors can help your HealthTech, MedTech, Health AI or Digital Health company, please email lloyd@nelsonadvisors.co.uk Nelson Advisors > European MedTech and HealthTech Investment Banking   Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk Nelson Advisors regularly publish Thought Leadership articles covering market insights, trends, analysis & predictions @  https://www.healthcare.digital     Nelson Advisors publish Europe’s leading HealthTech and MedTech M&A Newsletter every week, subscribe today!  https://lnkd.in/e5hTp_xb    Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk #NelsonAdvisors   #HealthTech   #DigitalHealth   #HealthIT   #Cybersecurity   #HealthcareAI   #ConsumerHealthTech   #Mergers   #Acquisitions   #Partnerships   #Growth   #Strategy   #NHS   #UK   #Europe   #USA   #VentureCapital   #PrivateEquity   #Founders   #SeriesA   #SeriesB   #Founders   #SellSide   #TechAssets   #Fundraising   #BuildBuyPartner   #GoToMarket   #PharmaTech   #BioTech   #Genomics   #MedTech Nelson Advisors LLP   Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Nelson Advisors @ 2026 Events   Digital Health Rewired > March 2026 > Birmingham, UK    NHS ConfedExpo   >  June 2026 > Manchester, UK    HLTH Europe >  June 2026, Amsterdam, Netherlands   HIMSS AI in Healthcare  >  July 2026, New York, USA   Bits & Pretzels >  September 2026, Munich, Germany     World Health Summit 2026  >  October 2026, Berlin, Germany   HealthInvestor Healthcare Summit >  October 2026, London, UK  HLTH USA 2026 >  October 2026, USA   Barclays Health Elevate >  October 2026, London, UK    Web Summit 2026 >  November 2026, Lisbon, Portugal     MEDICA 2026 >  November 2026, Düsseldorf, Germany   Venture Capital World Summit > December 2026 Toronto, Canada Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk

Clinical Intelligence: A Strategic Analysis of OpenEvidence and the Multi-Agent Medical AI Ecosystem The evolution of clinical decision support systems (CDSS) has reached a critical inflection point where traditional reference models are being supplanted by agentic, multi-model architectures. At the center of this transition is OpenEvidence, a platform that has ascended to a $12 Billion valuation in less than a year of public operations. This rapid scaling is fundamentally a response to the "human problem" identified by the platform’s founder, Daniel Nadler: the exponential expansion of medical knowledge, which is currently estimated to double every 73 days. For the contemporary physician, staying abreast of even a single sub-specialty would require approximately nine hours of daily reading, an impossibility that creates a systemic "dangerous gap" between breakthrough scientific discoveries and actual patient treatment. OpenEvidence positions itself as the "default operating system of medical knowledge," moving beyond simple search to provide an integrated, ad-supported "brain extender" for verified clinicians. This analysis explores the firm's competitive positioning, technical orchestration, venture capital trajectory and the inherent regulatory risks and growth strategies defining the next generation of medical super-intelligence. The Financial Architecture of Rapid Scaling The funding history of OpenEvidence represents one of the most aggressive capital-raising efforts in the history of healthcare technology. The company’s valuation trajectory, jumping from $1 Billion to $12 Billion within 12 months, reflects an investor consensus that clinical AI is transitioning from an experimental tool to essential infrastructure. The total capital raised by early 2026 reached approximately $750 Million, distributed across four high-velocity rounds. Venture Capital Trajectory and Investor Thesis The investor roster for OpenEvidence includes an elite tier of venture capital and institutional firms, each bringing specific strategic advantages. Lead investors such as Thrive Capital and DST Global are joined by Sequoia Capital, Google Ventures (GV), Nvidia, and the Mayo Clinic. The presence of Nvidia highlights the compute-intensive nature of the firm’s multi-agent architecture, while the Mayo Clinic’s involvement via its Platform Accelerate program provided early clinical validation and institutional trust. Funding Round Date Amount Raised Lead Investor(s) Valuation (Post-Money) Series A February 2025 $75 Million Sequoia Capital $1 Billion Series B July 2025 $210 Million GV, Kleiner Perkins $3.5 Billion Series C October 2025 $200 Million GV $6 Billion Series D January 2026 $250 Million Thrive Capital, DST Global $12 Billion The core thesis driving these investments is the belief that OpenEvidence is successfully bypassing traditional, slow-moving hospital procurement cycles. By utilising a Direct-to-Clinician (DTC) model, where the tool is free for verified doctors, the platform has achieved a daily active use rate of over 40% among U.S. physicians. This bottom-up adoption creates a massive user base that can then be monetised through high margin pharmaceutical advertising and future enterprise-level integrations. Revenue Mechanisms and Market Efficiency OpenEvidence reached a $100 Million annual revenue run rate in less than a year of commercial operations, making it one of the fastest-growing AI companies in any vertical. The monetisation strategy centres on a specialised pharmaceutical advertising model. While consumer social platforms might command Cost Per Mille (CPM) rates between $5 and $15, OpenEvidence’s uniquely targeted audience of verified prescribers commands CPMs between $70 and $1,000+. This allows for an average revenue per user (ARPU) of approximately $124, positioning the company to capture a significant portion of the $20 billion to $25 Billion annual U.S. digital pharma ad spend. Competitive Taxonomy and Market Displacement The clinical AI market is divided into three primary segments: legacy reference platforms, AI-native disruptors, and generalist AI giants. OpenEvidence’s dominance is currently predicated on its ability to bridge the gap between trustworthy, peer-reviewed content and the conversational interface of modern generative models. Legacy Reference Systems vs. AI-Native Models Incumbents such as UpToDate (Wolters Kluwer), DynaMed (EBSCO), and ClinicalKey (Elsevier) have long dominated the point-of-care market through human-authored summaries. However, the time required to navigate these narrative-heavy resources is a significant bottleneck. Comparative studies indicate that OpenEvidence provides a 18% reduction in the time spent answering clinical questions, saving approximately 30 seconds per encounter. Competitor Segment Core Value Proposition Vulnerability UpToDate Legacy Reference 7,400+ physician authors; deep narrative authority High subscription costs; slow to navigate Glass Health AI-Native Diagnostic reasoning; structured differential diagnoses Niche focus on reasoning vs. broad search AMBOSS Med-Ed/Reference Structured knowledge for students and residents Reference-first; less agentic than OpenEvidence OpenAI/Anthropic Generalist AI Massive reasoning power; HIPAA-compliant workspaces Lack of exclusive medical journal partnerships DynaMed Legacy Reference Explicit evidence grading; rapid updates Smaller topic coverage than UpToDate A critical differentiator for OpenEvidence is its "copyright-friendly" strategy. By securing official AI partnerships with the New England Journal of Medicine, JAMA, the NCCN, and the American College of Cardiology, OpenEvidence has created a data moat that protects it from the legal and accuracy-related challenges faced by generalist models like GPT-5 or Claude Healthcare. These partnerships allow the AI to ground its responses in figures, tables, and full-text clinical findings that are often behind paywalls or restricted for general training. The Big Tech Threat and the Focus Moat The entry of OpenAI (ChatGPT Health) and Anthropic (Claude for Healthcare) into the clinical space represents a significant challenge. These firms possess greater compute resources and broader AI research capabilities. However, OpenEvidence’s management argues that healthcare cannot be a "side hustle". The company’s focus on a single vertical, clinicians, allows for a deeper feedback loop, having already processed hundreds of millions of clinical consultations from verified U.S. physicians. This proprietary interaction data serves as a secondary moat, helping to fine-tune the "conductor" model for specific clinical nuances that generalist models may overlook. Technical Orchestration: The Conductor and the Orchestra of Agents OpenEvidence differentiates itself technically by utilising a "multi-AI agentic architecture". Rather than relying on a single, monolithic large language model (LLM) which might struggle with the specialised knowledge required for 160+ medical sub-specialties, the platform uses a hub-and-spoke topology designed to mimic a multidisciplinary care team in a top-tier academic hospital. The Hub-Spoke Topology and Routing Mechanism At the center of this architecture is a "conductor" AI. When a clinician submits a natural language query, the conductor model does not attempt to answer the question immediately. Instead, it performs a high-level intent analysis to determine which clinical expertise is required. The query is then dynamically routed to one or more proprietary, medically specialised sub-specialist models. This architectural choice is driven by the need for accuracy and the mitigation of hallucinations. Hierarchical multi-agent systems are particularly effective for multi-domain platforms where a root orchestrator can manage specialised workers for oncology, cardiology, or neurology. This structure prevents the "quadratic coordination constraint," where the complexity of an agent network scales leading to increased latency and error propagation. By using a directed tree structure, OpenEvidence ensures that communication flows strictly from parent to child, maintaining state isolation and preventing "groupthink" among the models. Synthesis and Verification Once the specialist models provide their outputs, the conductor AI synthesises the information into a single response. A hallmark of this output is the citation labeling system, which identifies sources by relevancy based on a proprietary evidence retrieval algorithm. This allows physicians to verify recommendations in real-time, accessing the underlying peer-reviewed literature directly from the chat interface. The technical excellence of this system is supported by what the firm calls "medical super-intelligence," a multimodal and multi cloud approach that ensures high availability and accuracy for high-stakes decisions at the point of care. Product Ecosystem and Expansion Strategies OpenEvidence has evolved from a medical search engine into a broader clinical workflow platform, categorised by its 2.0 release and the introduction of specialised communication tools. OpenEvidence 2.0 and Administrative Automation The 2.0 platform, launched in late 2024, addresses the "administrative burden" that consumes approximately 7.9 hours of a physician’s weekly schedule. Prior Authorisation: The platform can auto-draft prior authorisation letters, incorporating specific citations and medical evidence to justify treatment plans to insurers. Patient Communication: It generates evidence-based patient handouts and home care instructions, translating complex clinical guidelines into accessible language. Clinical Calculators: Inclusion of over 50 widely used clinical calculators within the primary interface reduces the need for external applications. The Clinical Documentation and Communication Suite The introduction of "Visits" and the "Doctor Dialer" positions OpenEvidence in direct competition with ambient scribe and telemedicine firms. Visits: An ambient clinical assistant that transcribes real-time patient encounters into structured documentation, integrating evidence-based suggestions directly into the draft. Doctor Dialer: A HIPAA-secure, privacy-centric communication tool that allows doctors to call or message patients from their personal devices while displaying their hospital or practice caller ID. This tool has already supported over 37 Million minutes of doctor-patient communication in its limited release phase. Feature Functionality Strategic Intent Medical Search Peer-reviewed synthesis with citations Establish trust and daily habit Visits Ambient scribing and note generation Capture encounter data and reduce burnout Dialer Secure calling and messaging Own the communication layer of the clinical workflow Open Vista Pharma R&D and trial matching Bridge the gap between life sciences and care Strategic Partnerships and Institutional Integration OpenEvidence’s growth is increasingly tied to its ability to embed itself within large-scale health systems and electronic health record (EHR) environments. Enterprise-Scale Deployments: Mount Sinai and Sutter Health In early 2026, OpenEvidence announced several landmark enterprise deals that signal a shift from a clinician-only tool to a system-wide standard of care. Mount Sinai Health System: This collaboration represents the first enterprise-scale deployment to extend access across the full clinical care team, including registered nurses and pharmacists. By embedding OpenEvidence directly into the Epic EHR, Mount Sinai aims to "democratise access" to clinical evidence, ensuring that any staff member can receive grounded answers within their existing workflow. Sutter Health: A similar integration allows Sutter clinicians to perform natural-language evidence searches directly within the Epic environment, solving the "last mile" problem of clinical AI where physicians are often reluctant to open separate browser tabs during a consultation. Life Sciences Collaboration: The Open Vista Initiative The partnership with Veeva to launch "Open Vista" in 2026 aims to leverage OpenEvidence’s reach, currently over 40% of US physicians, to accelerate clinical trial matching and improve the adoption of newly approved medicines. This initiative represents a third-order growth strategy: transitioning from a search tool to a two-sided marketplace connecting the point of care with the pharmaceutical R&D pipeline . Internationalisation and Global Medical Equity While primarily focused on the U.S. market, OpenEvidence has signalled significant plans for global expansion, beginning with English-first markets like the UK, Canada, and Australia. The Rwanda Pilot and Low-Resource Settings A strategic partnership with the Rwanda Biomedical Center (RBC) and "Resolve to Save Lives" (RTSL) highlights the platform’s potential for global health. In Rwanda, where access to current medical literature and specialist consultation is often limited, 45 leading clinicians are testing a customised version of OpenEvidence adapted for local resource constraints and specific knowledge requirements. This pilot serves as a blueprint for adapting clinical AI for low- and middle-income countries, aiming to reduce global inequities in the quality of care. Content Localisation and Multilingual Capabilities To support its global ambitions, OpenEvidence is developing multilingual capabilities. The partnership with Wiley, which includes over 400 journals and authoritative textbooks like Yamada's Textbook of Gastroenterology and Rook's Dermatology Handbook , provides the deep content library necessary for international specialists. This expansion of the "evidence layer" ensures that the platform remains grounded in peer-reviewed literature even as it adapts to different regional guidelines and medical practices. Risks, Regulatory Challenges and Performance Realities Despite its meteoric rise, OpenEvidence faces non-trivial risks regarding accuracy, regulatory classification, and the sustainability of its monetisation model. The Accuracy and Benchmark Controversy OpenEvidence has claimed to "ace" the USMLE with a perfect score, but independent quantitative evaluations have presented a more nuanced picture. In a study using the MedXpertQA dataset, which consists of complex medical subspecialty scenarios, OpenEvidence achieved an accuracy of only 34% to 41%. Furthermore, a large-scale assessment using a 1,000-item benchmark (combining MedQA and HealthBench tasks) found that generalist models like GPT-5 and Gemini 3 Pro outperformed specialised clinical tools in terms of completeness, communication quality, and systems-based safety reasoning. Model MedQA Accuracy HealthBench Consensus Score GPT-5 96.2% 97.0% Gemini 3 Pro 94.6% 90.5% OpenEvidence 89.6% 74.3% UpToDate Expert AI 88.4% 75.2% These findings suggest that while RAG-based systems are excellent for providing citations, the "reasoning" layer of generalist models may still be superior for complex clinical synthesis. There is a risk that if physicians become over-reliant on AI and the "conductor" model fails to route a question correctly, dangerous clinical errors could occur. Regulatory Classification: FDA SaMD The regulatory status of OpenEvidence as a "Software as a Medical Device" (SaMD) is a subject of ongoing debate. The FDA classifies medical software based on its intended use and the significance of the information it provides for decision-making. FDA Class Risk Description Regulatory Pathway Class I Low risk (General wellness, administrative tasks) Usually exempt Class II Moderate risk (Diagnosis, monitoring of non-life-threatening conditions) 510(k) or De Novo Class III High risk (Life-sustaining or high-risk diagnosis) Premarket Approval (PMA) OpenEvidence currently positions itself as a clinical decision support tool that "supports a healthcare professional but does not offer diagnosis or treatment" and "enables providers to independently review recommendations". This positioning typically allows for classification as a lower-risk device or even an exemption from certain premarket notifications. However, as the platform moves toward "medical super intelligence" and automates more of the diagnostic and treatment-planning workflow, the FDA may require more rigorous 510(k) clearances, particularly if the AI is seen as "driving" rather than just "informing" clinical management. Institutional Trust and Ethical Considerations The reliance on pharmaceutical advertising for monetisation introduces potential conflicts of interest. Critics may argue that an ad-supported model could subtly bias AI-generated treatment recommendations toward products from sponsors. OpenEvidence mitigates this by emphasising that its models are trained only on peer-reviewed journals and that advertising is displayed in the interface rather than integrated into the generated answers. Nevertheless, maintaining "brand trust" among a skeptical physician community remains a critical strategic priority. Clinical Intelligence: A Strategic Analysis of OpenEvidence and the Multi-Agent Medical AI Ecosystem M&A Potential: Targets and Exit Scenarios With a $12 Billion valuation and $750 Million in capital, OpenEvidence is positioned as a major consolidator in the healthcare AI space. Strategic Acquisition Targets The company has already demonstrated interest in acquisitions, reportedly acquiring the firm Amaro. Potential future targets include: Specialised AI Startups: Firms like Nested Knowledge (evidence-based medical search) or iDoctus and Ciplamed (regional medical platforms) could accelerate international expansion and content depth. Ambient Scribing Leaders: To bolster its "Visits" feature, OpenEvidence might target companies like Abridge Inc.or Nabla, which have deep experience in ambient documentation and EHR integration. Workflow Optimisation Tools: Startups focusing on prior authorisation automation or ICD-10 coding could further reduce the administrative burden for OpenEvidence users. Potential Acquirers While Daniel Nadler has expressed a commitment to independence, the scale and valuation of OpenEvidence make it a prime target for several types of acquirers : EHR Giants: Epic Systems or Oracle/Cerner could seek to acquire the platform to integrate the "default medical OS" into their proprietary ecosystems, offering a massive advantage to their hospital clients. Big Tech Players: Google (Alphabet), a major investor through GV, could seek to fully integrate OpenEvidence into its healthcare AI stack. Legacy Information Providers: Wolters Kluwer (UpToDate) or Elsevier could seek a defensive acquisition to pivot their business models toward generative AI. Conclusion: The Path Toward Medical Superintelligence OpenEvidence has successfully transitioned from a specialized research tool to a high-valuation infrastructure play by identifying and addressing the fundamental information bottleneck in modern medicine. Its success is rooted in a unique combination of high-fidelity data partnerships, a capital-efficient DTC adoption model and a sophisticated multi-agent technical architecture. However, the next phase of its evolution will be defined by its ability to maintain clinical accuracy in sub-specialty domains and navigate an increasingly complex regulatory landscape. The integration into major health systems like Mount Sinai and the expansion into administrative automation suggest that OpenEvidence is well on its way to becoming an essential layer of the clinical workflow. As the "human problem" of information overload persists, the adoption of "brain extenders" is no longer optional but a prerequisite for the safe and effective practice of medicine in the 21st century. The ultimate measure of OpenEvidence’s success will be its ability to translate its $12 Billion valuation into improved patient outcomes and a measurable reduction in the global gap between medical science and medical practice. Nelson Advisors > European MedTech and HealthTech Investment Banking   Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk Nelson Advisors regularly publish Thought Leadership articles covering market insights, trends, analysis & predictions @  https://www.healthcare.digital     Nelson Advisors publish Europe’s leading HealthTech and MedTech M&A Newsletter every week, subscribe today!  https://lnkd.in/e5hTp_xb    Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk #NelsonAdvisors   #HealthTech   #DigitalHealth   #HealthIT   #Cybersecurity   #HealthcareAI   #ConsumerHealthTech   #Mergers   #Acquisitions   #Partnerships   #Growth   #Strategy   #NHS   #UK   #Europe   #USA   #VentureCapital   #PrivateEquity   #Founders   #SeriesA   #SeriesB   #Founders   #SellSide   #TechAssets   #Fundraising   #BuildBuyPartner   #GoToMarket   #PharmaTech   #BioTech   #Genomics   #MedTech Nelson Advisors LLP   Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Nelson Advisors @ 2026 Events   Digital Health Rewired > March 2026 > Birmingham, UK    NHS ConfedExpo   >  June 2026 > Manchester, UK    HLTH Europe >  June 2026, Amsterdam, Netherlands   HIMSS AI in Healthcare  >  July 2026, New York, USA   Bits & Pretzels >  September 2026, Munich, Germany     World Health Summit 2026  >  October 2026, Berlin, Germany   HealthInvestor Healthcare Summit >  October 2026, London, UK  HLTH USA 2026 >  October 2026, USA   Barclays Health Elevate >  October 2026, London, UK    Web Summit 2026 >  November 2026, Lisbon, Portugal     MEDICA 2026 >  November 2026, Düsseldorf, Germany   Venture Capital World Summit > December 2026 Toronto, Canada Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk

Key Dynamics of the K-Shaped HealthTech Market The global healthtech ecosystem has entered a period of profound structural bifurcation, evolving away from the uniform cyclicality that defined previous decades toward a "K-shaped" trajectory. This dynamic represents a market reality where a distinct upper arm, composed of high-growth, clinically validated and AI-native "Health Tech 2.0" companies, achieves record valuations and operational scale, while a lower arm of legacy point solutions, high-burn startups, and undifferentiated wellness applications faces stagnation or liquidation. This divergence is not merely a financial artefact of high interest rates but a fundamental shift in the operating logic of the healthcare industry, where the premium has moved from "growth at all costs" to "profitable efficiency" and "measurable clinical ROI". The Theoretical Framework of K-Shaped Healthtech Recovery The transition to a K-shaped market marks a departure from traditional economic recovery models. While V-shaped recoveries imply a rapid industry-wide rebound and U-shaped recoveries suggest a prolonged but eventual uniform uplift, the K-shape describes a two-tier outcome where different segments of the same sector experience diametrically opposed fates. In the healthtech context, this began as a post-pandemic correction in 2022 and 2023, but by 2025, it hardened into a permanent structural feature. The upward arm reflects a "winner-take-most" dynamic, where capital concentration, technological superiority (specifically in Generative AI), and deep integration into clinical workflows create insurmountable moats. Conversely, the downward arm is populated by companies suffering from "valuation baggage", startups that raised capital at 20x to 50x revenue multiples during the 2021 peak but failed to achieve sustainable unit economics or product-market fit in a high-rate environment. The current environment amplifies long-standing inequality within the business landscape. Business revenue for firms focused on lower-income segments or those lacking clear efficiency gains is more vulnerable than for firms focused on wealthier clientele or systemic infrastructure. This dispersion risk means that headline indicators, such as total venture funding, can be deceptive. While aggregate funding for U.S. digital health startups rose to $14.2 Billion in 2025, a significant 35% increase from 2024, the total deal count actually dropped by 5%. This indicates that capital is no longer being distributed broadly across the "innovation engine" but is instead being funneled into a select few "Goliaths" that investors view as de-risked bets. Market Indicator 2024 Benchmark 2025 Observed 2026 Forecast Total U.S. Funding $10.5B $14.2B $17.0B - $18.0B Deal Volume (Count) 509 482 450 - 475 Average Deal Size $20.7M $29.3M $32.0M+ Mega-Deal Share (> $100M) 21% 42% 45% - 50% Series B Average Size $29.3M $51.6M $55.0M AI-Enabled Funding Share 37% 54% 60%+ Capital Dynamics and the Rise of the Mega-Fund The financial engine of the K-shaped market is the emergence of the "mega-fund", venture capital firms with at least $500 million to deploy, such as Andreessen Horowitz (a16z), General Catalyst, and Kleiner Perkins. These firms have become the primary market-makers, responsible for the vast majority of mega-deals (raises over $100 Million). In 2025, 80% of all mega-deals featured a mega-fund on the term sheet. This creates a self-reinforcing loop: these "winner" companies receive the capital necessary to out-invest competitors in R&D and customer acquisition, while the "have-nots" are forced into austerity measures, leading to a "thinning of the middle". This concentration is particularly evident in the Series B and C stages, which have become the "valley of death" for many healthtech startups. While Series A activity remains robust as investors seek "fresh" companies without the valuation overhang of 2021, the bar for Series B has risen dramatically. Companies in the middle must now demonstrate not just growth, but a "Rule of 40" performance (growth rate plus free cash flow margin) to attract follow-on capital. For instance, Hinge Health, a representative of the Health Tech 2.0 cohort, reported 72% annualised revenue growth with 26% free cash flow margins in late 2025, a performance that investors now view as the gold standard. Startups unable to reach these benchmarks are finding themselves reliant on unlabeled bridge or extension rounds, which accounted for 35% of all financings in 2025. The M&A landscape further illustrates this K-shaped divergence. Activity surged 61% to 195 deals in 2025, but the nature of these transactions was split. On the upward arm, strategic acquisitions were used to build "horizontal platforms." Examples include Innovaccer acquiring Humbi AI to expand its hospital infrastructure and CoachCare acquiring VitalTech to deepen its care coordination capabilities. These are offensive moves designed to prevent incumbents like Epic or Oracle from replicating feature sets. On the downward arm, however, M&A increasingly took the form of "distress sales" by companies that could not clear the necessary hurdles for subsequent funding. Private Equity (PE) has been a significant beneficiary of this, with a 600% increase in healthtech spend in 2025 as firms snap up distressed assets with solid underlying IP but broken capital structures. The "Health AI X Factor": Causal Mechanisms of Growth Artificial Intelligence is the primary technological driver of the K-shaped bifurcation. It is no longer viewed as a novelty but as "bedrock infrastructure" for the next generation of healthcare companies. In 2025, AI-enabled companies commanded a 19% premium on average deal size, reflecting an investor belief that AI can fundamentally alter the unit economics of healthcare delivery. Bessemer Venture Partners identifies this as the "Health AI X Factor," which provides four distinct competitive advantages: unprecedented velocity, margin expansion, platform potential, and clinical outcomes. Scaling velocity has historically been the primary weakness of healthcare software. Due to long sales cycles, complex integrations, and the "human-intensive" nature of care, it often took a decade or more for companies to reach $100 million in ARR. AI-native companies, however, are hitting these milestones in under five years. This is achieved by automating the "operating layer" of healthcare, specifically clinical and non-clinical workflows, which captured 42% of total sector funding in 2025. Companies like Abridge and OpenEvidence have transitioned from promising pilots to essential infrastructure by automating documentation and triage, reducing clinician burnout, and cutting documentation time by 30 minutes per day per provider. Health AI Pillar Mechanism of Action Strategic Implication Unprecedented Velocity AI accelerates R&D and sales cycles Compression of time-to-scale ($100M ARR in <5 yrs) Margin Expansion Automation of administrative labor Non-linear scaling; revenue growth outpaces headcount Platform Potential Move from point solution to OS Integration into EHR/EPR as essential infrastructure Clinical Outcomes Precision diagnostics and triage Shift to "clinician-in-the-loop" decision support The competitive landscape for AI is now a battle between "agentic" systems developed by tech giants and specialized clinical tools from independent innovators. Amazon Connect Health, launched in late 2025, represents a major move into this space, offering a system that handles everything from patient verification and scheduling to ambient documentation and medical coding. By integrating natively with Epic, the largest U.S. EHR system, Amazon is positioning itself as a core utility for providers. This challenges independent "scribe" startups to either build broader horizontal platforms or risk being commoditised by the cloud giants who own the underlying data infrastructure. Market Generations: Health Tech 1.0 vs. 2.0 The K-shaped market is best understood as a generational split. "Health Tech 1.0" (roughly 2015-2021) was defined by top-line growth fueled by pandemic tailwinds, often at the expense of unit economics and business model sustainability.This cohort remains essentially flat in public markets, with many companies trading below their IPO prices or struggling with high churn. "Health Tech 2.0" (2024-2026), by contrast, is a new class of companies—including Waystar, Tempus, HeartFlow,and Omada Health, that represent a more disciplined approach to healthcare innovation. These 2.0 companies are characterized by profitable or near-profitable operations and proven ROI that works regardless of macroeconomic conditions. In 2025, new health tech stocks rose by 18%, matching the performance of the S&P 500 and significantly eclipsing the Nasdaq Emerging Cloud Index, which fell 7%. This "comeback story" in the public markets has reopened the IPO window, with six companies going public between 2024 and 2025, adding $36.6 billion in fresh market capitalization. However, a "trust gap" remains: even these 2.0 companies trade at a 10-20% discount compared to high-growth software in other sectors, as investors wait for multiple quarters of proven sustainability before awarding them SaaS-level multiples. Feature Health Tech 1.0 (Legacy) Health Tech 2.0 (Modern) Primary Value Prop "Digital Front Door" / Access Clinical ROI / Workflow Efficiency Economic Logic Growth at all costs (VC-subsidized) Profitable efficiency / High FCF Business Model Often B2C or shallow B2B Deeply embedded B2B / Infrastructure Public Market View Discounted; high volatility Rebounding; "Gold Standard" emerging AI Integration Bolt-on or superficial Native; "Agentic" workflows The Consumer Paradox: More Striving, Less Thriving The K-shaped dynamic extends beyond balance sheets into the lives of consumers and patients. A global study of 300,000 voices reveals a profound "progress-sentiment gap": while quality-of-life indicators are at all-time highs, people report feeling 9% worse physically and mentally than in previous years. This is the "wellness treadmill", a pattern of higher effort yielding diminishing emotional returns, where "better" is never quite good enough. This mental health decline, down 11% since 2022—has made behavioural health the strongest driver of telehealth adoption, accounting for 63.9% of all telehealth claims in late 2025. However, the way consumers interact with health technology is bifurcating by income. Households earning over $150,000 are increasing their spend on "thriver" categories like longevity, preventative care, and out-of-home experiences, with spending growth approaching 20%. Conversely, lower-income households (<$50,000) are trading down, delaying purchases, or relying on credit to cover basic health needs. This split has revitalised the D2C market for specialised clinical services. While generic wellness apps are struggling, 2025 saw a wave of activity in D2C lab testing from companies like Oura, Whoop, and Hims. This trend is driven by younger consumers (Gen Z and Millennials) who are twice as likely as older generations to use natural products and cutting-edge digital technologies, provided they see data-backed evidence of efficacy. The "wellness" market, now valued at $2 trillion globally, is becoming increasingly segmented: one side seeks price efficiency for basic needs, while the other seeks time efficiency and scientific expertise at any price. Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk Regulatory Catalysts: The Access and Outcome Mandate Regulatory bodies in 2025 and 2026 are acting as decisive market-makers, further entrenching the K-shaped divide. The Centers for Medicare & Medicaid Services (CMS) and the FDA have shifted their focus toward "accountability and integration" rather than mere "innovation promise". The CMS "ACCESS Model" (Advanced Care Coordination through Enhanced Support Services), launching in 2026, exemplifies this shift. It moves away from fee-for-service toward "outcome-aligned payments," where providers are rewarded based on the share of patients meeting outcome targets for chronic conditions like hypertension, diabetes and musculoskeletal pain. To support this, the "TEMPO" pilot allows manufacturers of devices that have not yet received full FDA authorisation to be used within the ACCESS model, generating real-world data to support future marketing submissions. This creates a massive competitive advantage for companies with integrated, technology-supported care models over those selling isolated point solutions. Simultaneously, the FDA has tightened its oversight of "wellness" claims. A 2025 warning letter to WHOOP regarding its blood pressure insights signaled that any technology intended for diagnosis or mitigation of disease would be strictly regulated as a medical device. This "regulatory floor" is rising; the requirement for "total product lifecycle" (TPLC) monitoring and rigorous data stewardship means that smaller startups without the capital for clinical trials or regulatory consultants are increasingly locked out of the market. Regulatory Initiative Focus Area Market Winner ACCESS Model (CMS) Outcome-aligned payments Integrated care platforms (RPM/CCM) TEMPO Pilot (FDA) Real-world data generation Fast-track device manufacturers Part D Redesign (IRA) Manufacturer cost-sharing Efficient "TechBio" platforms PCCP Framework Adaptive AI evolution "Safe and Transparent" AI models Procurement Act 2023 (UK) Value over price Clinically validated SME partners In the United Kingdom, the NHS has embarked on a similar "left shift," moving care from acute hospitals to community settings. The shift to Value-Based Procurement (VBP) in 2026 marks the end of "cheapest price wins". Procurement decisions must now evidence long-term patient outcomes and total pathway cost savings. While this favours high-quality innovators, it places a massive administrative burden on SMEs, who account for 85% of the 80,000 NHS suppliers but struggle to navigate the "patchwork of frameworks" across 42 Integrated Care Systems. Cybersecurity as a Strategic Gatekeeper Cybersecurity has transitioned from a backend technical requirement to a primary differentiator for market access. In 2024 and 2025, the healthcare sector faced its most severe wave of cyberattacks, with 92% of organizations reporting a breach. The average cost of a healthcare breach has risen to $408 per record—three times higher than the cross-industry average. In this climate, "security rigor" is a prerequisite for even entering an RFP. The K-shaped divide is visible in certification adoption. HITRUST has emerged as the "gold standard" for regulated healthcare environments, offering a prescriptive framework that simplifies vendor evaluation and builds "instant credibility" with buyers and investors. While SOC 2 is often seen as a "legal floor" or "baseline," hospital systems and large payers are increasingly mandating HITRUST for any vendor touching ePHI. Achieving this certification can provide a 464% ROI by speeding up sales cycles by up to 50%. Companies on the lower arm of the K that neglect this "security-by-design" find themselves increasingly excluded from the $125 billion that the healthcare industry is projected to spend on cybersecurity products through 2025. The Extinction Event: Anatomy of Failure in the Lower Arm The downward arm of the K-shaped market is defined by a series of high-profile failures and liquidations. The "cleansing" of the market has targeted companies that relied on "fake it till you make it" strategies or those that failed to diversify after pandemic demand peaked. Builder.ai , which raised $445 Million at a $1.3 Billion valuation, filed for bankruptcy in May 2025 after revelations that its "AI-powered" development was largely performed by offshore human labour, a case of "wearing a fake moustache and calling it innovation". Similarly, companies like Cue Health and Wheel Health, which built their business models on COVID-19 testing and travel nurse demand, respectively, collapsed as demand normalized and they lacked a sustainable pivot. These failures underscore a broader lesson: in a K-shaped economy, market timing is everything, but surviving the "inevitable correction" requires actual technology and financial governance (such as hiring a CFO, which Builder.ai notably lacked for two years). Company Status Primary Cause of Decline/Failure Builder.ai Bankruptcy (2025) Fraudulent AI claims; high burn without CFO Cue Health Collapsed (2023-24) Post-pandemic demand collapse (testing) Babylon Health Insolvency (2023) Low-margin, unsustainable telehealth model Olive AI Liquidated (2023) High integration complexity; over-expansion Lilium Insolvency (2025) High regulatory barriers; technical failure Cerebral Restructured (2024) DOJ/DEA investigation into prescribing The collapse of these "Health Tech 1.0" stars has cleared the way for the "Health AI X Factor" cohort to capture market share. However, it has also raised the risk premium for the entire sector. Even high-quality assets are being priced lower due to "elevated risk premiums" and "geopolitical exposure" (particularly related to China licensing and API sourcing).Due diligence now routinely includes modelling for trade policy shocks and the impact of the Inflation Reduction Act on pricing corridors. Case Study: The "Goliath" vs. "David" Workflow War The concentration of power among "Goliaths" is the most significant competitive dynamic of 2026. This is best observed in the struggle for control over the "healthcare workflow stack." In 2025, clinical and non-clinical workflow captured $5.96 billion in funding, a massive lead over any other category.Abridge and OpenEvidence emerged as the "infrastructure" winners, using mega-deals to move from point solutions to horizontal platforms. At the same time, Amazon's entry with "agentic AI" through Amazon Connect Health has created a new baseline for what "good" looks like: a system that is available 24/7, integrates with Epic, and handles the full patient journey from initial call to final billing. Independent "Davids" are responding by buying each other to build horizontal breadth before the giants can move. For example, Judi Health raised $400 million and immediately acquired Amino Health to expand into patient navigation. This "strategic acceleration" is a defensive necessity; without scale, point solutions face the risk of being reduced to "features" within the EHR or cloud providers' ecosystems. Conclusion: Strategic Imperatives for the 2026-2027 Cycle The K-shaped healthtech market is no longer a temporary phenomenon but a structural reality defined by the "haves" of AI infrastructure and the "have-nots" of legacy models. For stakeholders to navigate this divide, several strategic imperatives have emerged: Prioritise Profitable Efficiency over Raw Growth: The "Health Tech 2.0" gold standard is the Rule of 40. Companies must demonstrate a clear path to $100 Million ARR within five years while maintaining strong free cash flow margins. Embed AI into the Core Operating Layer: Success is no longer about "using AI" but about owning the workflow. The market rewards systems that provide "agentic" solutions, handling complex, multi-step tasks that reduce human labour costs. Secure "Gold Standard" Certifications: Trust is a market gatekeeper. HITRUST certification has moved from optional to mandatory for high-value contracts, providing a tangible ROI by accelerating sales and reducing audit friction. Align with Value-Based and Outcome-Driven Policy: Both the CMS (ACCESS/TEMPO) and the NHS (VBP) are rewarding integrated, data-rich models that prove long-term cost savings. Pure-play software without clinical evidence will struggle to maintain reimbursement. Target the "Thriver" Demographic or Engineer Strategic Affordability: The consumer split requires a two-track product strategy. Premium, high-expertise products will find growth at the top of the income arm, while value-driven, "essential" services must focus on radical price efficiency to serve the squeezed middle and lower cohorts. As the market heads toward 2027, the "IPO window" will likely remain open only for those on the upward arm of the K. The "tale of two markets" will continue to unfold, with the few that demonstrate durability and scale capturing the vast majority of the $6 trillion in projected worldwide IT spending. The healthtech industry is no longer about the "promise of innovation" but about the "rigor of impact". Nelson Advisors > European MedTech and HealthTech Investment Banking   Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk Nelson Advisors regularly publish Thought Leadership articles covering market insights, trends, analysis & predictions @  https://www.healthcare.digital     Nelson Advisors publish Europe’s leading HealthTech and MedTech M&A Newsletter every week, subscribe today!  https://lnkd.in/e5hTp_xb    Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk #NelsonAdvisors   #HealthTech   #DigitalHealth   #HealthIT   #Cybersecurity   #HealthcareAI   #ConsumerHealthTech   #Mergers   #Acquisitions   #Partnerships   #Growth   #Strategy   #NHS   #UK   #Europe   #USA   #VentureCapital   #PrivateEquity   #Founders   #SeriesA   #SeriesB   #Founders   #SellSide   #TechAssets   #Fundraising   #BuildBuyPartner   #GoToMarket   #PharmaTech   #BioTech   #Genomics   #MedTech Nelson Advisors LLP   Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Nelson Advisors @ 2026 Events   Digital Health Rewired > March 2026 > Birmingham, UK    NHS ConfedExpo   >  June 2026 > Manchester, UK    HLTH Europe >  June 2026, Amsterdam, Netherlands   HIMSS AI in Healthcare  >  July 2026, New York, USA   Bits & Pretzels >  September 2026, Munich, Germany     World Health Summit 2026  >  October 2026, Berlin, Germany   HealthInvestor Healthcare Summit >  October 2026, London, UK  HLTH USA 2026 >  October 2026, USA   Barclays Health Elevate >  October 2026, London, UK    Web Summit 2026 >  November 2026, Lisbon, Portugal     MEDICA 2026 >  November 2026, Düsseldorf, Germany   Venture Capital World Summit > December 2026 Toronto, Canada Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk

20 Future Belgian HealthTech and MedTech Leaders The Ascendance of the Belgian HealthTech and MedTech Ecosystem: Analysis of 20 Future Leaders The Belgian healthcare innovation landscape has undergone a tectonic shift over the last decade, evolving from a traditional pharmaceutical stronghold into a globally recognised "Health and Biotech Valley". This maturation is not merely a product of historical legacy but the result of a deliberate, multi-layered strategy involving institutional catalysts, regional specialisation and a robust venture capital framework that prioritises deeptech inter-d isciplinarity The convergence of biotechnology, medical devices (MedTech) and digital health solutions has created an environment where the boundaries between hardware, software and biology are increasingly porous. Institutional Foundations and the Spin-Off Paradigm The engine of Belgian innovation is rooted in its research institutions, most notably the Flanders Institute for Biotechnology (VIB) and imec. The VIB has established a formidable track record, launching 39 spin-offs and securing over €1.8 Billion in venture capital. This institutional success is measured not only in capital but in scientific impact; for every Euro of core funding from the Flemish government, the VIB generates approximately €12 for the regional economy. The institute’s holistic approach extends beyond basic research to include infrastructure development, such as the bio-incubators in Ghent, Leuven and Brussels, which provide the essential wet-lab space and mentorship required for early-stage scaling. Simultaneously, imec has leveraged its status as a world leader in nanoelectronics to address the "memory wall" and data processing bottlenecks inherent in modern medical AI. Through its venturing arm, imec.xpand and its accelerator program, imec.istart, the centre has become a primary architect of the Belgian MedTech sector, fostering startups that utilise semiconductor precision for biological monitoring and therapeutic intervention. The integration of these two giants, VIB’s biological mastery and imec’s electronic precision, defines the unique value proposition of the Belgian ecosystem. Institutional Impact Metrics (2023-2024) VIB (Biotech) imec (MedTech/Digital) Spin-offs Launched (Total) 39 Over 30 (Active in Health) Venture Capital Secured €1.8 Billion €941 Million (Annual Revenue) Gross Value Added (Annual) €1 Billion N/A (Global Entity) Employment Supported 11,000 Jobs >5,000 Employees Regional Specialisation and the Merger of Clusters Belgium’s geographic compacting facilitates a level of collaboration that is rare in larger jurisdictions. Wallonia has carved out a dominant position in Advanced Therapy Medicinal Products (ATMPs) and nuclear medicine. The BioWin cluster in Wallonia represents over 90% of the region’s health-biotechnology players, focusing on a "Health and Biotech Valley" vision that integrates vaccines, biomedicines, and cellular therapies. This specialisation is supported by the BioPark in Charleroi and the LégiaPark in Liège, which offer specialized infrastructure for radiopharmaceutical production and GMP cell-therapy operations. In Flanders, the recent merger of the industry organization flanders.bio and the spearhead cluster MEDVIA signals a strategic move toward a unified representation of the sector. By bringing together "red, green, and white" biotech with healthtech developers, hospitals, and academic institutes, the new organisation aims to address global challenges with a single, more efficient voice. This merger is expected to streamline the "Say Yes to the US" program, which facilitates the entry of Flemish companies into the North American market, recognising that international expansion is critical for the survival of high-growth MedTech firms. Analysis of the 20 Future Belgian Leaders in HealthTech and MedTech The following entities represent the vanguard of Belgian medical innovation, characterised by deep technical moats, significant capital backing, and leadership teams with proven expertise in navigating the complex regulatory landscapes of the EMA and FDA. 1. AgomAb Therapeutics: Mastering the Fibrotic Microenvironment AgomAb Therapeutics, situated in Ghent, has emerged as a powerhouse in the treatment of fibrotic and degenerative diseases. Founded in 2017 by Paolo Michieli, the company focuses on growth factor mimetics that modulate regenerative pathways. The master-stroke of AgomAb’s strategy was its recent $100 Million Series C funding round, which provides the runway necessary to move its lead candidates through late-stage clinical trials. By targeting the hepatocyte growth factor (HGF) and its receptor MET, AgomAb aims to achieve what was previously considered impossible: the reversal of established fibrosis in organs such as the liver and lungs. 2. AstriVax: A Paradigm Shift in Vaccine Deployment AstriVax is a prime example of the high-impact spin-offs emerging from the KU Leuven Rega Institute. Under the leadership of CEO and co-founder Hanne Callewaert, the company is commercializing a versatile vaccine platform based on the yellow fever 17D (YF17D) vaccine. This technology allows for the rapid engineering of vaccines against emerging infectious diseases and therapeutic targets in oncology. Having secured €30 Million in seed funding, a record for the region, AstriVax is advancing toward clinical Proof of Concept in 2024, with a scientific advisory board that includes global luminaries like Peter Piot. 3. Vertical Compute: The Infrastructure for On-Device Medical AI Founded in 2024 as an imec spin-off, Vertical Compute addresses the fundamental physical limitation of modern computing: the memory bottleneck. Led by CEO Sylvain Dubois and CTO Sebastien Couet, the company has raised a total of €57 Million in seed funding to develop a 3D memory architecture. By stacking memory directly on top of logic, the platform achieves 100x improvement in the execution of Large Language Models (LLMs) and reduces energy consumption by 80%. While a deep-tech company, the implications for MedTech are profound, enabling real-time, high-security processing of genomic data and physiological signals directly on portable medical devices without relying on vulnerable cloud infrastructure. Vertical Compute Funding Trajectory Seed Phase 1 (Jan 2025) Seed Extension (Mar 2026) Amount Raised €20 Million €37 Million Total Funding €20 Million €57 Million Lead Investor imec.xpand Quantonation Strategic Support Eurazeo, XAnge PMV, Wallonie Entreprendre 4. Axithra: Photonics-on-Chip for Point-of-Care Monitoring Axithra, a joint spin-off of imec and Ghent University, is revolutionising therapeutic drug monitoring (TDM). Led by CEO Leander Van Neste, the company utilises Raman-on-chip spectroscopy to measure drug concentrations in blood in real-time. Their primary application focuses on lactam antibiotics in intensive care units (ICUs). In critical care settings, the variation in patient metabolism is extreme; Axithra’s technology allows clinicians to adjust dosages every few minutes rather than waiting hours for a central lab report, directly impacting survival rates and preventing antibiotic resistance. 5. Novadip Biosciences: Regenerative Orthopedics from Stem Cells Novadip Biosciences, based in the BioPark Charleroi, represents the pinnacle of Walloon excellence in ATMPs. Founded by Denis Dufrane, the company utilises an adipose-derived stem cell platform to create 3D tissue implants for bone reconstruction. Their flagship product aims to heal complex bone defects that are currently untreatable. Having secured €22 Million in Series B funding, Novadip is entering late-stage clinical trials, positioning itself to capture a significant share of a potential €13.5 Billion market. 6. Minze Health: The Digitalisation of Urology and Pelvic Health Minze Health has established itself as a leader in home-based urological diagnostics and digital therapeutics. Under the leadership of newly appointed CEO Thomas Moore—a veteran of the US MedTech market, Minze is scaling its platform for Benign Prostatic Hyperplasia (BPH) and Overactive Bladder (OAB). Their products, which include automated bladder diaries and home-based uroflowmetry, enable continuous monitoring outside the clinic, improving both diagnostic accuracy and patient compliance. The company is currently preparing for a Series B fundraising round to support its US commercial expansion. 7. Mona Health: Retinal Analysis as a Diagnostic Window````` Mona Health, founded by Olivier Ménage, utilises artificial intelligence to analyse retinal images for the early detection of glaucoma and other systemic conditions. Based in Mol, the company operates on the principle that the retina is a non-invasive window into the body’s vascular and neurological health. By providing automated screening tools to optometrists and primary care physicians, Mona Health addresses the global shortage of ophthalmologists and facilitates early intervention for vision-threatening diseases. 8. Skinetix: Biomechanical Intelligence via Smart Sportswear Skinetix is an imec and VUB spin-off that has successfully integrated electromyogram (EMG) sensors directly into textile fibers. Led by Joris De Winter and Kevin Langlois, the company provides real-time, field-based measurement of muscle activity. While the initial market focus is on professional sports organizations like international soccer clubs, the long-term MedTech value lies in post-injury recovery and neuro-rehabilitation. By linking sensor data with personalised AI biomechanical models, Skinetix provides clinicians with quantitative data on muscle fatigue and movement quality that was previously only available in specialised gait labs. 9. Specifix: Automating the Preoperative Surgical Workflow Specifix, an Antwerp-based healthtech startup, focuses on the high-precision requirements of orthopaedic surgery. Founded by Dr. Alejandra Ortega, Dr. Soha Mahdi, and Prof. Dr. Matthias Vanhees, the company provides automated 3D planning software for wrist fracture fixation. The platform allows surgeons to upload CT scans and receive a fully automated preoperative plan, identifying the optimal personalised implants to stabilise the fracture. This reduction in operative time and increase in placement precision leads to faster patient recovery and fewer surgical complications. 10. FiriX Therapeutics: Inhibiting Ferroptosis in Organ Survival FiriX Therapeutics is a 2025 spin-off from the University of Antwerp focusing on ischemia-reperfusion injury (IRI). Their lead candidate, FXT-001, is a first-in-class ferroptosis inhibitor designed to treat tissue damage that occurs when blood supply returns to oxygen-deprived organs. This mechanism is critical in organ transplantation and the treatment of myocardial infarctions. FiriX has already demonstrated that FXT-001 is "organ-saving" in pig and human ex vivo transplant settings, representing a major advancement in transplant medicine. 20 Future Belgian HealthTech and MedTech Leaders 11. Sightera Biosciences: Generative Drug Design via Tumoroid Screening Sightera Biosciences utilises AI to revolutionise oncological drug discovery. Led by Hendrik Vercammen and Maxim Le Compte, the company integrates robotic high-throughput screening with generative AI to identify drug-response patterns in patient-derived "tumoroids". This approach ensures that drug development is patient-relevant from the earliest stages, significantly increasing the probability of clinical success and reducing the multi-billion-dollar cost of drug failure. 12. Stimalia: Bioelectronic Implants for PTSD Stimalia addresses the global crisis in mental health through neuromodulation. The company is developing a miniaturised, injectable bioelectronic implant that provides drug-free therapy for Post-Traumatic Stress Disorder (PTSD) via continuous nerve stimulation. Led by a team of veterans from the neuro-modulation industry, including Olivier Ménage and Pascal Doguet, Stimalia’s device represents the transition of psychiatry from purely chemical interventions to precise electronic modulation of the nervous system. 13. Precirix: Nanobody-Based Radiopharmaceuticals Precirix is a prominent player in the targeted radiation therapy sector, developing radiopharmaceuticals based on single-domain antibodies (nanobodies). These molecules are designed to deliver radioisotopes directly to tumor cells with high specificity, sparing healthy tissue. Operating within the robust nuclear medicine ecosystem of Wallonia, Precirix leverages the region’s specialised logistics and isotope production to advance its clinical pipeline for several solid tumour indications. 14. Univercells: The Democratisation of Bioprocessing Univercells is redefining the cost structure of vaccine and biologic production. Founded by Hugues Bultot and Jose Castillo, the company develops modular manufacturing platforms that allow for high-throughput production in a small footprint. This technology is critical for the "Health and Biotech Valley" initiative, as it enables the regional production of gene and cell therapies at a fraction of the cost of traditional cleanroom facilities. 15. Bioxodes: Redefining Haemorrhagic Stroke Treatment Bioxodes is a Walloon drug development firm focusing on Ir-CPI, a first-in-class drug designed to prevent thrombosis and neuro-inflammation in patients suffering from haemorrhagic stroke. Unlike existing treatments that increase the risk of re-bleeding, Bioxodes’ molecule offers a safer profile. The company is currently moving toward a pivotal Phase 2b trial, with a strategic goal of gaining market approval by 2030, addressing a massive unmet need in neurological emergency care. 16. ABSCINT: Next-Generation Molecular Imaging ABSCINT is a molecular imaging company with two lead programs in cardiovascular disease and oncology. Their technology utilises nano-bodies for the imaging of vulnerable atherosclerotic plaques and tumour-specific antigens. By providing clinicians with a more precise view of biological activity at the molecular level, ABSCINT enables personalised treatment adjustments that are not possible with traditional anatomical imaging like CT or MRI. The company aims to launch its first diagnostics in the EU and North America by 2028. 17. iTeos Therapeutics: Precision Cancer Immunotherapy iTeos Therapeutics, a BioWin member, has transitioned from a promising startup to a clinical leader in cancer immunotherapy. The company recently released encouraging clinical data regarding its lung cancer treatment, which focuses on modulating the immune microenvironment of tumors. Their success reinforces Belgium’s reputation as a centre for high-value oncology research and provides a model for other startups aiming for IPO or major acquisition. 18. Thameus (Baby Detect): Genomic Preventive Medicine Thameus is the spin-off responsible for the "Baby Detect" project, which has pioneered genomic newborn screening in Liège. While traditional screening focuses on a handful of diseases, Baby Detect uses targeted next-generation sequencing (NGS) to screen for over 160 treatable conditions from a single heel-prick sample. This project exemplifies the shift toward "predictive medicine," where intervention begins before symptoms appear, fundamentally altering the life-trajectory of children with rare genetic disorders. 19. Sequana Medical: Active Fluid Management in Chronic Disease Sequana Medical, based in Ghent, has developed the alfapump®, a fully implantable, wirelessly charged pump system.The device is designed to manage fluid balance in patients with liver cirrhosis and congestive heart failure by automatically moving excess fluid from the abdomen to the bladder for natural elimination. With over $52 Million in funding, Sequana is a leader in the medical engineering space, providing a significant quality-of-life improvement for patients who would otherwise require frequent, painful drainage procedures. 20. Brailsports: The AI Engine for Physiological Optimisation Brailsports is a joint spin-off from imec, the University of Antwerp, and Ghent University. Led by CEO Erika Lutin, the company has developed an AI platform that accurately estimates an individual’s fitness and fatigue by analyzing cardiac and power data. While initially focused on professional cycling teams, the platform’s core technology has broad medical applications in the prevention of overtraining syndrome and the monitoring of cardiac rehabilitation patients. Brailsports represents the vanguard of "digital coaching," where medical-grade insights are used to optimise human performance and prevent injury. Cross-Sectoral Analysis and Market Dynamics The Belgian HealthTech sector is characterised by an exceptionally high density of R&D and clinical development actors. This density creates a "cluster effect" where information and talent circulate rapidly. For example, the merger of MEDVIA and FlandersBio was driven by the recognition that biotech and medtech are no longer distinct silos. Modern therapies, such as the ATMPs developed by Novadip, require specialised medical devices for delivery, while digital platforms like Awell Health are needed to manage the complex care pathways associated with these advanced treatments. Core Pillars of Belgian HealthTech Specialisation Representative Leaders Strategic Hubs Advanced Therapies (ATMP) Novadip, AgomAb, Univercells BioPark Charleroi Nuclear Medicine Precirix, ABSCINT, Trasis Liège/LégiaPark AI & Digital Diagnostics Mona Health, Minze, Baby Detect imec (Leuven), Antwerp Precision MedTech Axithra, Specifix, Sequana Ghent/Leuven The Role of Venture Capital and Public Support Public-private partnerships are the lifeblood of the Belgian ecosystem. The Flemish investment company PMV and the Walloon equivalent Wallonie Entreprendre (WE) act as anchor investors, providing the stability necessary to attract international venture capital firms like V-Bio Ventures, Kurma Partners, and Earlybird Health. In 2024, BioWin members secured €12.5 Million in combined funding, while larger scale-ups like AgomAb have demonstrated the ability to attract $100 Million rounds from global investors. This capital is supported by government subsidies from VLAIO (Flanders) and the SPW (Wallonia), which often provide non-dilutive funding for early-stage R&D. Future Outlook: Challenges in Scaling and Internationalisation As Belgium moves toward 2030, the primary challenge remains the transition from "frontier research" to "meaningful industrial transformation". While the country excels at launching startups, scaling them into global market leaders requires access to even larger capital pools and a deep understanding of the US healthcare market. The "Health and Biotech Valley" initiative is designed to address this by fostering international alliances and providing specialised training for founders. Furthermore, the integration of innovation into the Belgian hospital system remains a hurdle. The "Health on Stage" symposium in 2026 addressed this by inviting hospitals to present their "real-world challenges" to the startup community, flipping the traditional sales-pitch model. Projects like SIM BLOOD, a serious game for transfusion training developed by Cliniques de l'Europe and PLAY IT, won Innovation Awards for demonstrating tangible hospital impact, suggesting that the future of Belgian HealthTech lies in co-creation between engineers and clinicians. Conclusion: The Convergence of Biology and Bits The Belgian HealthTech and MedTech ecosystem has entered a period of unprecedented convergence. The 20 leaders identified in this report are not merely developing better medical products; they are redefining the mechanisms of diagnosis, therapy and patient management through the integration of artificial intelligence, photonics, and regenerative biology. Supported by world-class institutions like VIB, imec and a regional strategy that emphasises specialised clusters and international proximity, Belgium is well-positioned to remain a global leader in health innovation for the foreseeable future. The continued success of these firms will depend on their ability to maintain technical excellence while navigating the commercial complexities of a globalized healthcare economy. Nelson Advisors > European MedTech and HealthTech Investment Banking   Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk Nelson Advisors regularly publish Thought Leadership articles covering market insights, trends, analysis & predictions @  https://www.healthcare.digital     Nelson Advisors publish Europe’s leading HealthTech and MedTech M&A Newsletter every week, subscribe today!  https://lnkd.in/e5hTp_xb    Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk #NelsonAdvisors   #HealthTech   #DigitalHealth   #HealthIT   #Cybersecurity   #HealthcareAI   #ConsumerHealthTech   #Mergers   #Acquisitions   #Partnerships   #Growth   #Strategy   #NHS   #UK   #Europe   #USA   #VentureCapital   #PrivateEquity   #Founders   #SeriesA   #SeriesB   #Founders   #SellSide   #TechAssets   #Fundraising   #BuildBuyPartner   #GoToMarket   #PharmaTech   #BioTech   #Genomics   #MedTech Nelson Advisors LLP   Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Nelson Advisors @ 2026 Events   Digital Health Rewired > March 2026 > Birmingham, UK    NHS ConfedExpo   >  June 2026 > Manchester, UK    HLTH Europe >  June 2026, Amsterdam, Netherlands   HIMSS AI in Healthcare  >  July 2026, New York, USA   Bits & Pretzels >  September 2026, Munich, Germany     World Health Summit 2026  >  October 2026, Berlin, Germany   HealthInvestor Healthcare Summit >  October 2026, London, UK  HLTH USA 2026 >  October 2026, USA   Barclays Health Elevate >  October 2026, London, UK    Web Summit 2026 >  November 2026, Lisbon, Portugal     MEDICA 2026 >  November 2026, Düsseldorf, Germany   Venture Capital World Summit > December 2026 Toronto, Canada Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk

20 Future Norwegian HealthTech and MedTech Leaders The Strategic Evolution of Norwegian HealthTech and MedTech: Analysis of 20 Emerging Leaders and the National Innovation Ecosystem The Norwegian life sciences landscape is currently undergoing a systemic transition, evolving from a research-intensive academic environment into a globally integrated commercial powerhouse. This metamorphosis is facilitated by a unique confluence of high-trust public health data, a robust sovereign wealth environment and a maturing infrastructure of specialised clusters such as Norway Health Tech, the Oslo Cancer Cluster and Aleap. As the global healthcare market increasingly demands precision medicine, decentralised care models and AI-augmented diagnostics, Norway has positioned itself as a "forerunner" region. This status is characterised by a "human scale" that allows for rapid testing and validation of sophisticated technologies within a public healthcare system, often referred to under the regional identity of "HealthFjords". The following report provides an analysis of twenty future leaders within this sector, the technological breakthroughs they oversee and the second-order socio-economic impacts of their work on the global stage. The Vanguard of Radiopharmaceuticals and Targeted Oncology The most capital-intensive and scientifically rigorous segment of the Norwegian ecosystem is currently focused on targeted alpha therapies (TAT) and precision diagnostics. This sector leverages Norway’s historical expertise in nuclear science and oncology to address malignancies traditionally resistant to conventional treatments. 1. Jasper Kurth and Thor Medical: Scaling Alpha Emitter Production Thor Medical ASA, directed by CEO Jasper Kurth, represents a critical shift in the global supply chain for modern oncology. Kurth, who possesses over fifteen years of leadership experience in the pharmaceutical and med-tech industries, including a significant tenure as General Manager of Radiology Nordics at Bayer, is spearheading the development of the AlphaOne commercial-scale plant at Herøya Industrial Park. The company focuses on the production of alpha-emitters derived from naturally occurring thorium, providing a reliable and environmentally friendly alternative to traditional nuclear reactor-based production. The strategic significance of Thor Medical lies in its proprietary production process, AlphaCycle™, which requires no irradiation, thereby reducing regulatory hurdles and environmental impact. In early 2025, the company secured a NOK 90 Million loan facility from Innovation Norway, complementing a private placement and retail offering that raised approximately NOK 200 Million. This funding ensures that the AlphaOne facility is fully capitalised through its 2026 production ramp-up. Strategic Milestone Metric / Detail Timeline / Status Source Capital Raising Private Placement and Retail Offering (NOK 173M initially) December 2024 Various Debt Financing Innovation Norway Loan Facility (NOK 90M) January 2025 Various Operational Launch Final Investment Decision (FID) for AlphaOne March 2025 Various Projected Output 25,000 patient doses annually Within 5 years Various Market Valuation Market capitalisation of approximately NOK 737.7M December 31, 2024 Various Kurth’s leadership is defined by a transition from pilot-stage validation to industrial-scale execution. The ability to produce medical isotopes at Herøya, where the pilot facility was ceremonially opened by the Norwegian Minister of Trade, positions Norway as a primary exporter in the radiopharmaceutical sector. The high-quality production has already been verified by international customers, leading to multi-year sales agreements that secure nearly full capacity utilization for the AlphaOne plant before construction begins. 2. Esmaeil Dorraji and ImmunoQuest Therapeutics: Precision ADC Development In the biopharmaceutical domain, Esmaeil Dorraji, founder and Chief Scientific Officer of ImmunoQuest Therapeutics, is advancing a novel class of Antibody-Drug Conjugates (ADCs). The company’s lead candidate, NAZ-001, is designed to target the p95HER2 protein—a truncated form of the HER2 receptor found exclusively in tumor cells. This selectivity is vital, as p95HER2 is associated with high rates of metastasis and resistance to existing HER2-targeted therapies such as trastuzumab. Dorraji’s approach exemplifies the "precision" in precision medicine. By focusing on a biomarker absent in healthy tissue, ImmunoQuest reduces the systemic toxicity that often limits the efficacy of oncological drugs. The potential application of NAZ-001 extends beyond breast cancer to ovarian, lung, and colorectal cancers, indicating a broad total addressable market (TAM). The company recently joined the Oslo Cancer Cluster to leverage the ecosystem's connections with academic researchers and international investors. 3. Chee Yong and Elpis Biopharmaceuticals: Engineering Long-Lasting Cell Therapies Elpis Biopharmaceuticals, co-founded by Co-CEO Chee Yong, is a clinical-stage cell therapy company that recently joined the Oslo Cancer Cluster to establish its European presence. While based in Boston and Singapore, the company’s expansion into Norway reflects the country’s growing leadership in advanced therapeutics and clinical trial infrastructure. Under Yong’s leadership, Elpis is developing technologies that treat solid tumors by targeting multiple tumour pathways simultaneously. A core innovation in the Elpis pipeline is the ability to engineer immune cells that last longer in the patient's body without the harmful side effects typically associated with intensive cell therapies. The company's therapies are currently in clinical trials in China, with interim results anticipated by the end of 2025. 4. Anders M. Dale and Precision Health: Multimodal Clinical Decision Support The integration of artificial intelligence into clinical workflows is spearheaded by Anders M. Dale, founder and CEO of Precision Health. Dale, an internationally recognized researcher with deep ties to both Norwegian and American academic institutions, focuses on developing multimodal tools for neurology, psychiatry, and oncology. Precision Health addresses diagnostic challenges such as Alzheimer’s disease, severe mental disorders, and prostate cancer. Dale’s leadership emphasizes the necessity of being part of a collaborative ecosystem. By joining the Oslo Cancer Cluster, Precision Health has gained access to a network of university hospitals and global pharma partners, which Dale credits with helping the company avoid common developmental mistakes and fine-tuning its strategy. The company serves as a bridge between the clinical excellence of Norway and the commercial dynamism of the United States. Innovations in Respiratory and Critical Care Monitoring The Norwegian MedTech sector is dominated by hardware-software hybrids that automate vital sign monitoring, thereby reducing clinician fatigue and enhancing patient safety in acute settings. 5. Øystein Theodor Ødegaard-Olsen and Eupnea: Intelligent Respiratory Surveillance Eupnea AS, co-founded by CEO Øystein Theodor Ødegaard-Olsen and Andreas Tunset, has emerged as a leader in wireless respiratory monitoring. The company’s core technology is a small, wireless sensor that transmits respiratory data via 5G networks to a Norwegian cloud-based data centre. The clinical insight driving Eupnea is that respiratory rate is often the most reliable early indicator of physiological deterioration, yet it is the vital sign most frequently recorded manually or omitted during busy shifts. Ødegaard-Olsen, who has a background in interdisciplinary group rehabilitation and clinical research at the University of Bergen, has overseen the validation of the sensor in prospective clinical studies. In 2025, Eupnea was recognised as a finalist for the Health Startup of the Year award, highlighting its potential to improve outcomes at institutions like Haraldsplass Deaconess Hospital. Operational Feature Specification / Impact Source Transmission Protocol 5G Network to Norwegian Cloud (no Bluetooth required) Various Clinical Validation RespX accelerometer-based wireless sensor study Various Target Utility Early detection of cardiac arrest and emergency admission Various Staff Impact Reduces manual counting workload for nurses Various 6. Trude Tingvoll and Respinor: Diaphragm Ultrasound for Ventilation Weaning Respinor AS, led by CEO Trude Tingvoll, has reached significant international milestones with its RESPINOR DXT® technology. The device provides continuous, operator-independent ultrasound monitoring of the diaphragm to predict successful weaning from mechanical ventilation. This is critical for the 3.2 Million patients using respirators annually, as prolonged ventilation increases both costs and patient risk. Tingvoll’s leadership has been instrumental in securing the FDA’s "Breakthrough Device" designation in late 2024 and the CE Mark under the EU MDR in August 2025. Furthermore, she participated in the NOME (Nordic Mentor Network for Entrepreneurship) U.S. delegation, which provided concrete investor leads and regulatory insights crucial for the company's expansion into the American market. 7. Fridtjof Heyerdahl and EpiGuard: High-End Isolation Systems EpiGuard, founded in 2015 by Fridtjof Heyerdahl, MD, PhD, specialises in high-end medical isolation and transport systems. The company’s flagship product, the EpiShuttle, was developed to allow for the safe transport of patients with highly infectious diseases while protecting healthcare personnel. Heyerdahl’s expertise in product development and manufacturing has positioned EpiGuard as a key player in global health security. The company is a portfolio business of Inven2, the technology transfer office for the University of Oslo and Oslo University Hospital. EpiGuard’s success demonstrates how Norwegian clinical innovation can be rapidly scaled to meet international demand during pandemics and other public health crises. 8. Nicolas Elvemo and GlucoSet: Continuous Glucose Control in the ICU Nicolas Elvemo, co-founder of GlucoSet, focuses on metabolic monitoring in the Intensive Care Unit (ICU). GlucoSet develops tools for accurate continuous glucose control to reduce patient mortality and hospital costs associated with improper glucose management in critical care settings. The company, which emerged as a spin-off from NTNU, utilizes advanced sensor technology to provide real-time data to clinicians. Elvemo’s leadership has been characterised by a commitment to rigorous technical validation, ensuring that the sensor can operate reliably in the high-stakes environment of an ICU. Leadership in Women's Health and Reproductive Technology FemTech is a burgeoning sub-sector in Norway, where entrepreneurs are addressing long-overlooked conditions such as maternal safety, endometriosis and fertility. 9. Hege Hansen and Induvita: Elevating Gynecological and Maternal Standards Induvita AS, led by CEO Hege Hansen, was named the "Health Startup of the Year" (Årets helsegründer) for 2025. The company develops medical devices and training simulators designed to make vaginal examinations and gynaecological procedures more comfortable and safer for women. Hansen’s strategy involves a comprehensive portfolio, including the Runa and Ayla training simulators, the Vega speculum (launching in 2026), and the Iola induction catheter. The Iola device is a balloon catheter designed to make labor induction more predictable and safer for both the clinician and the mother. Hansen’s leadership is notable for its advocacy; she views the award not just as a business success, but as a signal that women's health is finally receiving the clinical and commercial attention it deserves. 10. Dilip K. Prasad and Spermotile: AI-Enhanced Male Fertility Solutions Professor Dilip K. Prasad from UiT The Arctic University of Norway is the founder of Spermotile, a deep-tech MedTech company revolutionizing assisted reproduction technology (ART). Spermotile utilises AI-powered sperm selection technology to improve the success rates of In-Vitro Fertilisation (IVF). Prasad has successfully raised $4 Million from high-profile sources, including the European Research Council (ERC) and the Research Council of Norway. The company is currently navigating the stringent regulatory pathways for CE marking and FDA clearance, a process required for deep-tech medical devices before commercial scaling. Prasad’s leadership is characterised by an interdisciplinary approach, combining advanced microscopy, fluid mechanics and bio-AI. 11. Kristian Larsen and Diagnostrix: Non-Invasive Diagnostics for Endometriosis Diagnostrix is a joint venture between the Biolink Group (Norway) and Oratel Diagnostics (USA), directed by CEO Kristian Larsen. Larsen, a serial entrepreneur with over twenty years of experience in business development, has positioned Diagnostrix to solve the long-standing challenge of diagnosing endometriosis, which currently often requires invasive surgery. The Diagnostrix solution uses color-detection technology for saliva testing, providing a low-cost and non-invasive alternative to traditional diagnostics. The team, which includes R&D Director Mariana T. Eiane, MD, and synthetic chemist Einar Bakstad, PhD, aims to make women's health diagnostics radically more accessible on a global scale. 20 Future Norwegian HealthTech and MedTech Leaders Digital Health, AI and Remote Patient Management Norway’s mature digital infrastructure provides a testing ground for AI-native startups that aim to automate clinical documentation and decentralise care follow-up. 12. Jorunn Thaulow and Medbric: Transforming Clinical Documentation with AI Dr. Jorunn Thaulow, a physician and researcher, founded Medbric in late 2024 to address the dual challenges of antibiotic overuse and the administrative burden of clinical notes. Medbric’s ambient scribe solution, Aila, uses speech-to-note technology to generate personalised clinical documentation, allowing doctors to focus on patient interaction rather than their computer screens. Within fifteen months of its launch, Medbric captured a market share of approximately 25-30% of all general practitioners in Norway and expanded into ten hospitals across the Helse Vest and Helse Midt-Norge regions. Thaulow’s leadership is defined by her "research-first" mentality, collaborating closely with the NorWAI research centre to ensure the AI agents are tailored to the Norwegian language and clinical requirements. 13. Anders Eikenes and Oivi: AI-Powered Diabetic Retinopathy Screening Anders Eikenes, co-founder of Oivi and a former co-founder of Huddly, has pioneered an accessible AI-camera system for the early detection of diabetic eye disease. Eikenes’ vision is to provide an affordable, automated screening solution that can be deployed in primary care settings or community clinics, rather than requiring patients to visit specialised eye centres. Eikenes brings a strong commercial and product-design background to the company. His leadership has focused on creating a "human-centred" device that is intuitive for non-specialist healthcare workers to operate, thereby democratising access to complex diagnostic imaging. 14. Espen Riskedal and AgeLabs: Predictive Models for Early Disease Detection AgeLabs, founded by Espen Riskedal and Karl Trygve Kalleberg in 2017, utilizes machine learning to identify biological markers for early disease detection. Riskedal has led the company through various R&D projects with public institutions, focusing initially on age-related diseases and later expanding into the predictive modeling of COVID-19 severity. Under Riskedal’s guidance, AgeLabs has secured nearly $1 Million in funding and earned nominations for Best Health Tech Startup at the Nordic Startup Awards. The company’s work represents the transition from reactive medicine to proactive, data-driven health interventions. 15. Marius Mathisen and Pletly: Harmonising Care for Vulnerable Populations Marius Mathisen is the CEO of Pletly, a Norwegian-American healthtech firm that provides a connected care platform for individuals with cognitive challenges, such as dementia or autism. The platform bridges the communication gap between family members and professional caregivers, ensuring a single, accurate source of information for the "circle of care". Mathisen’s leadership highlights the importance of empathy in HealthTech design. Founded by individuals with personal caregiving experience, Pletly has signed strategic agreements with special education academies and senior care providers like NewCourtland in Philadelphia, demonstrating the international scalability of the Norwegian "connected care" model. Company Focus Area Key Leadership Core Technology Source Medbric Clinical AI Jorunn Thaulow Ambient Scribe (Aila) Various Oivi Ophthalmology Anders Eikenes AI-integrated Camera Various AgeLabs Predictive Health Espen Riskedal ML for Biomarkers Various Pletly Connected Care Marius Mathisen Coordination Platform Various Neurotechnology and Robotic Rehabilitation Advances in cybernetics and biofeedback are enabling new methods for treating neurological disorders and physical impairments that were previously considered untreatable. 16. Cathrine Ro Heuch and Nordic Brain Tech: Digital Biofeedback for Neurological Care Cathrine Ro Heuch, CEO and co-founder of Nordic Brain Tech, leads a spin-off from NTNU and St. Olav's Hospital that aims to transform migraine care globally. The company’s flagship product, Cenli, is a digital biofeedback solution for home use that helps patients predict and prevent migraine attacks without the side effects of medication. Heuch’s leadership is notable for its personal motivation, she has lived with migraines since her youth and her strategic utilisation of the Norwegian ecosystem. She has been named a "Rising Star" and appeared on the "40 under 40" list for leadership talent. Under her direction, Nordic Brain Tech successfully completed the NOME program and expanded its reach into the U.S. market through collaborations with the Mayo Clinic. 17. Saeid Hosseini and Vilje Bionics: Empowering Patients with Arm Exoskeletons Saeid Hosseini, CEO and co-founder of Vilje Bionics, is overseeing the development of VilPower, a full-arm exoskeleton designed to restore movement for people with arm and hand paralysis. The system combines shoulder, elbow, wrist, and hand support in an innovative AI-driven device. Hosseini, who moved to Norway in 2011 and co-founded the company at the age of 24, is motivated by the desire to use technology to bridge physical limitations. The company has raised $4 Million in funding and partnered with leading European medical institutions to validate the device's ability to mimic natural motion. Hosseini’s leadership represents the potential of impact-driven entrepreneurship to solve massive global health challenges affecting over 60 Million people. Strategic Leadership in Biotech and Diagnostic Infrastructure 18. Jonas Hallén and Calluna Pharma: Tackling Fibrotic and Inflammatory Disease Calluna Pharma, founded in 2024 through the merger of Oxitope and Arxx Therapeutics, is directed by Co-founder and Chief Medical Officer Jonas Hallén. The company focuses on developing therapeutics for inflammatory and fibrotic diseases, such as idiopathic pulmonary fibrosis (IPF), where there is a significant unmet need for better-tolerated treatments. Hallén, who brings drug development experience from Boehringer Ingelheim and Novartis, has overseen the advancement of CAL101, an S100A4 targeting monoclonal antibody currently in Phase II clinical trials. Calluna successfully raised €75 Million (approximately $81.7 Million) in a Series A round, one of the largest such rounds in the Norwegian biotech sector, to advance its pipeline. Hallén’s leadership emphasises the need for Norwegian startups to build international networks to access specialised manufacturing and clinical expertise. 19. Morten Isaksen and Bio-Me: Scaling Microbiome Diagnostics Dr. Morten Isaksen, founder and CEO of Bio-Me, is developing a Precision Microbiome Profiling platform. This technology allows for the rapid, high-throughput analysis of the human gut microbiome, which is increasingly linked to diseases ranging from obesity to autoimmune disorders. Isaksen has successfully utilised the Aleap Pre-Seed Fund to accelerate Bio-Me’s development program and market introduction. His leadership is central to Norway's efforts to become a hub for personalised nutrition and microbiome-based diagnostics, bridging the gap between molecular biology and clinical application. 20. Stig Morten Borch and SpinChip Diagnostics: Rapid Point-of-Care Testing Stig Morten Borch, founder of SpinChip Diagnostics, is leading the development of a cutting-edge diagnostic platform designed for rapid and accurate point-of-care testing. SpinChip’s technology aims to provide lab-quality results within minutes, which is critical in emergency settings such as suspected cardiac events. Borch’s leadership has focused on the engineering challenges of miniaturizing complex diagnostic procedures into a centrifugal microfluidic chip. The company represents the high-tech manufacturing capability that exists within the Norwegian MedTech cluster, where precision engineering meets clinical diagnostics. Analysis of the Supporting Ecosystem: Clusters and Tech Transfer The success of these twenty leaders is predicated on a highly coordinated support system that mitigates the risks associated with early-stage life science ventures. The Role of Technology Transfer Offices (TTOs) Inven2, the TTO for the University of Oslo and Oslo University Hospital, is a pivotal player in this ecosystem, managing a portfolio of approximately 50 companies with a combined value of around NOK 5 Billion. In 2024 alone, Inven2-backed startups raised NOK 670 Million in private capital. Similarly, NTNU Technology Transfer AS has established 73 spin-off companies, many of which are focused on HealthTech and MedTech. These organisations provide the legal, commercial and financial expertise required to move research from the laboratory to the market. TTO / Incubator Core Metric (2024-2025) Key Outcome Source Inven2 116 New Inventions; NOK 670M raised Transition of researchers to entrepreneurs Various NTNU TTO 73 Spin-off companies to date Scaling academic IP into MedTech firms Various Aleap >18 Alumni; $19M Capital raised Norway's largest health startup incubator Various Norway Health Tech 308 Members; 38 International activities National driver of public-private collaboration Various Collaborative Test Environments: The Smart Care Lab The "Smart Care Lab," a service provided by Norway Health Tech, allows companies like DNV Imatis and Dignio to document the clinical and operational benefits of their solutions in real-world municipal settings. This independent validation is crucial for overcoming the "challenges of the Norwegian market," where high-quality standards can sometimes slow down the adoption of new technologies. For example, DNV Imatis demonstrated time savings of 390 hours annually in a single municipality, providing the "hard data" required for larger-scale implementation. Market Trends and the Future of Norwegian Health Innovation The Norwegian HealthTech and MedTech sectors are characterised by several emerging trends that will define the next decade of growth. 1. Capital Concentration and Global Integration Global venture capital data from 2024-2025 indicates a shift toward fewer but larger funding rounds. While overall deal counts are lower than historical averages, the average financing round in the MedTech sector reached $36 Million in the first half of 2025. This "capital concentration" favors mature startups and AI-native firms that can demonstrate clear clinical value and a path to international scaling. 2. The Rise of "HealthFjords" as a Regional Brand Western Norway, centered around Bergen, has launched the "HealthFjords" identity to position the region as an international powerhouse for health technology. This initiative, supported by the Eitri Innovation Centre and major grants from Agenda Vestlandet, emphasises "human scale" innovation—small enough to be agile, but large enough to lead in diagnostics and digital patient pathways. 3. Sustainability and Social Impact There is an increasing focus on the "sustainability" of healthcare systems. Leaders like Hege Hansen (Induvita) and Saeid Hosseini (Vilje Bionics) are not just focused on profitability but on creating a more "dignified" and "accessible" healthcare experience. This alignment with Nordic values, trust, equality and sustainability, is viewed as a competitive advantage in international markets where health equity is becoming a priority. Conclusion The future leaders of Norwegian HealthTech and MedTech are distinguished by their ability to combine deep clinical research with sophisticated engineering and AI integration. From Jasper Kurth’s industrialisation of medical isotopes at Thor Medical to Cathrine Ro Heuch’s decentralised migraine care at Nordic Brain Tech, these innovators are solving some of the most complex problems in modern medicine. The success of these individuals is supported by a robust national strategy that prioritises public-private collaboration, internationalisation, and the documentation of real-world clinical benefits. As Norway continues to transition its economy, the HealthTech and MedTech sectors represent a significant pillar of future growth, capable of delivering both economic value and profound improvements in patient lives worldwide. The transition from "garage startups" to "global leaders" is well underway, secured by a unique ecosystem that balances Nordic values with international commercial ambition. Nelson Advisors > European MedTech and HealthTech Investment Banking Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk Nelson Advisors regularly publish Thought Leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital Nelson Advisors publish Europe’s leading HealthTech and MedTech M&A Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk #NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTech Nelson Advisors LLP Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Nelson Advisors @ 2026 Events Digital Health Rewired > March 2026 > Birmingham, UK NHS ConfedExpo > June 2026 > Manchester, UK HLTH Europe > June 2026, Amsterdam, Netherlands HIMSS AI in Healthcare > July 2026, New York, USA Bits & Pretzels > September 2026, Munich, Germany World Health Summit 2026 > October 2026, Berlin, Germany HealthInvestor Healthcare Summit > October 2026, London, UK HLTH USA 2026 > October 2026, USA Barclays Health Elevate > October 2026, London, UK Web Summit 2026 > November 2026, Lisbon, Portugal MEDICA 2026 > November 2026, Düsseldorf, Germany Venture Capital World Summit > December 2026 Toronto, Canada Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk

20 Future Romanian HealthTech and MedTech Leaders The technological landscape of Romania has experienced a seismic shift between the fiscal years of 2024 and 2026, transitioning from a secondary outsourcing destination into a primary forge for high-valuation HealthTech and MedTech intellectual property. This metamorphosis is not merely anecdotal; it is substantiated by a radical escalation in capital inflow and a strategic pivot toward "Born Global" enterprises that prioritise international scalability from their inception. The year 2025 stands as a historical inflection point for the region, where a single landmark financing event, the $165 Million Series C round for the robotics firm Dexory, nearly equaled the entire venture capital output of the Romanian ecosystem in 2024. This surge in liquidity, backed by global institutional heavyweights such as Atomico, Eurazeo and Lakestar, signals that the operational ceiling for Romanian-founded companies has been permanently elevated, transitioning the narrative from a regional hub to a consistent producer of global category leaders in medical and assistive technologies. The maturation of the sector is further evidenced by the increasing density of DeepTech and AI-native startups. By early 2026, the Romania Tech Startup Association (ROTSA) and accelerators like Techcelerator had mapped over 100 artificial intelligence startups with Romanian roots, many of which are dedicated to solving high-complexity problems in oncology, radiotherapy, microbiome analysis and feline longevity. This report analyses 20 such leaders, representing a mix of high-growth scale-ups, innovative pre-seed ventures and visionary individuals who are redefining the intersection of healthcare and technology. The Vanguard of Robotics and Assistive Technology The intersection of hardware, sensor fusion, and healthcare has emerged as a dominant vertical within the Romanian innovation space. These companies leverage advanced engineering backgrounds, often rooted in automotive and aerospace sectors, to address fundamental human mobility and supply chain challenges. 1. Dexory: Autonomous Systems in the Healthcare Supply Chain While Dexory is often categorized within the logistics and robotics sector, its implications for MedTech are profound. Founded by Andrei Danescu (CEO), Oana Andreea Jing, and Adrian Negoita, the company develops autonomous platforms that provide real-time digital twin technology for warehouse operations. The $165 Million Series C round in October 2025 provided the capital necessary to deploy these systems at a global scale. In the context of healthcare, Dexory’s technology addresses the critical requirement for high-precision logistics in the pharmaceutical and medical device industries. The digital twin capabilities allow for the granular monitoring of sensitive medical inventories, ensuring that temperature-controlled environments are maintained and that the traceability of life-saving equipment meets stringent regulatory standards. By automating data collection, Dexory eliminates the human error inherent in medical supply chains, a second-order effect that significantly enhances patient safety by ensuring that the right medical assets are available exactly when needed. 2. dotLumen: Advanced Mobility for the Visually Impaired Founded by Cornel Amariei, dotLumen represents the pinnacle of Romanian assistive technology. Amariei, an inventor and researcher who previously led sensor innovation at Continental Automotive, has applied automotive-grade autonomous driving principles to human mobility. dotLumen produces smart glasses that utilize 3D scanners and vibrating sensors to assist the blind in navigating complex environments. By 2025, dotLumen had secured approximately $30 Million in total funding, including an €11 Million grant from the European Innovation Council (EIC) Fund. The technological mechanism involves real-time spatial mapping, where the device "sees" the environment and provides haptic feedback to the user, effectively acting as a high-tech alternative to traditional guide dogs or walking canes. This innovation is a testament to the Romanian ecosystem’s ability to repurpose industrial engineering expertise for direct clinical and social impact. AI-Driven Diagnostics and Radiography Leaders Radiology and medical imaging have become the primary battlegrounds for AI adoption in Romania, driven by a deep talent pool in computer vision and machine learning. 3. Rayscape: The Maturation of Computer Vision in Radiology Formerly operating as XVision, Rayscape has evolved into a comprehensive digital assistant for radiologists. Co-founded by Stefan Iarca, Cristian Avramescu, Bogdan Bercean, and Andrei Tenescu, the platform utilises deep learning to analyse chest X-rays and lung CT scans. The company’s trajectory from its 2018 founding in Timisoara to its 2024-2026 expansion exemplifies the successful scaling of a Romanian MedTech startup. Rayscape’s impact is measured by clinical efficiency; in pilot projects at the County Emergency Clinical Hospital in Timisoara, the platform allowed radiologists to interpret 20% more images per day by prioritizing pathological cases. As of 2024, the company secured additional seed funding of €460,000, bringing its total financing to nearly €2 Million as it targets Western European and North American markets. The success of Rayscape is foundational to the Romanian MedTech narrative, proving that local algorithms can meet international clinical standards. 4. Synaptiq Technologies: Precision in Oncological Planning Synaptiq Technologies addresses the "contouring" bottleneck in radiotherapy, where doctors must manually delineate tumors and organs at risk before treatment can begin. The team, led by Dragoș Dușe, Dragoș Grama and Marius Stănescu, brings together academic excellence from Heidelberg, Amsterdam and Bucharest. Dragoș Dușe, a physicist and machine learning researcher, previously designed algorithms at the German Cancer Research Institute. Synaptiq’s AI reduces the time required for treatment planning from several hours to a matter of minutes, directly increasing the throughput of oncology departments. Nominated for "Best DeepTech Startup" and "Healtech & Longevity Innovator" at the 2026 Romania Startup Awards, the company represents a shift toward specialised AI that integrates deeply into the clinical workflow. Leading HealthTech Entities Primary Vertical Key Founders / Leaders Funding / Status (2025/26) Dexory Robotics / Supply Chain Andrei Danescu, Oana Jinga $165M Series C dotLumen Assistive Tech Cornel Amariei $30M Total Rayscape Radiology AI Stefan Iarca, Cristian Avramescu €1.93M Total Synaptiq Technologies Oncology AI Dragoș Dușe, Marius Stănescu Best DeepTech Nominee NostraBiome Microbiome / Biotech Calin Popescu, Valerio Lo Giudice Best Fundraising Performer The Cat Health Company Longevity Biotech Alex Voda, Alex Bacita €1.8M Total Digitail Veterinary SaaS Sebastian Gabor, Ruxandra Puiu $37M Total Apollo AI Technologies Pharma / NLP Mihaela Onofrei, Vlad Trandafir Female-Led Startup 2026 Hilio (Atlas) Mental Health Mihai Bran, Mihnea Bran Telemedicine Leader Orbotix MedTech / Robotics Bogdan Ochiana, Gregory Letare €7M Seed Microbiome, Longevity and Precision Medicine The Romanian sector is increasingly exploring the frontiers of longevity and microbiome analysis, moving from reactive medicine to proactive, personalised health interventions. 5. NostraBiome: The Personalisation of Immune Response NostraBiome is a DeepTech health company that utilises AI simulations to analyse the human microbiome, specifically targeting Inflammatory Bowel Disease (IBD) and oncology-related digestive issues. Founded by Calin Popescu, a serial entrepreneur with over 100 patents, the company was born from Popescu’s own decade-long struggle with IBD. By identifying unique microbial signatures, NostraBiome provides chronological recommendations to "hack" the inflammatory code of the individual patient. The company’s leadership team includes CTO Valerio Lo Giudice and CMO Dr. Dragomir Radu Dumitru, a specialist at OncoHelp, the largest oncology center in Western Romania. NostraBiome has achieved remarkable results, with 90% of IBD patients in their studies reaching sustained remission. The startup’s success at the 2026 Romania Startup Awards, winning for revenue growth and fundraising, underlines the market’s appetite for precision medicine solutions that bridge the gap between AI and biological data. 6. The Cat Health Company (TCHC): Feline Longevity as a Human Proxy Founded in 2024 by Oxford-trained scientist Alex Voda and former Charles River Labs senior scientist Alex Bacita, The Cat Health Company focuses on feline longevity. While the immediate product is longevity medicine for companion cats, the underlying mission is to accelerate human therapy discovery by using cats as a biological model for aging research. TCHC secured €1.8 Million in seed funding, with participants including Early Game Ventures and Alex Zhavoronkov, the founder of the AI-driven pharma unicorn Insilico Medicine. The company’s approach involves in silico research to explore drug candidate libraries faster and more cost-effectively than traditional methods. By targeting the root causes of aging rather than just symptoms, TCHC is positioning Romania as a key node in the global longevity biotech network. Veterinary and Pharmaceutical Innovations The automation of clinical workflows and the democratisation of pharmaceutical data have emerged as critical sub-sectors, significantly reducing the administrative and cognitive load on healthcare providers. 7. Digitail: Revolutionising Veterinary Practice Management Digitail, co-founded by Sebastian Gabor, Ruxandra Puiu, and Alexandru Tabolcea, is an all-in-one veterinary practice management platform (PIMS) that utilises AI to automate clinic workflows and pet owner communication. In November 2025, the company raised a $23 Million Series B round, bringing its total funding to $37 Million. The platform’s global reach is extensive, supporting 10,000 veterinarians across 40 countries. Digitail’s success is a prime example of the "Born Global" Romanian strategy, where the founders moved rapidly to capture international market share, backed by elite investors like Google’s Gradient Ventures and Atomico. The second order insight here is the role of VetTech as a precursor to human HealthTech trends, particularly in remote monitoring and automated patient engagement. 8. Apollo AI Technologies: AI-Native Pharma Solutions Founded in Iaşi in 2022, Apollo AI Technologies specializes in NLP and data mining for the healthcare sector. Led by Mihaela Onofrei and Vlad Trandafir, the company developed "Diabeta," a medical chatbot for diabetologists and "Pharmachat," which processes the specifications of all medicines approved in Romania. Apollo’s most significant contribution is the creation of a map encompassing 1.7 Million drug-to-drug interactions, a tool that has been deployed in pharmacy chains to prevent adverse reactions. As the winner of the "Female-Led Startup of the Year" award in 2026, Apollo AI exemplifies the integration of computational linguistics into the pharmaceutical safety chain. Mental Health and Telemedicine Pioneers Mental health, once a neglected area in Eastern European healthcare, has seen a surge in digital innovation driven by the normalisation of remote care. 9. Hilio (formerly Atlas): The Maturation of Tele-Mental Health Hilio, founded by psychiatrist Mihai Bran and Mihnea Bran, represents the evolution of the Romanian telemedicine market. Originally known as Atlas, the platform has transitioned into a comprehensive mental wellness ecosystem, providing access to therapy, coaching and corporate wellness programs. Dr. Mihai Bran’s work highlights the critical intersection of clinical expertise and entrepreneurial spirit, using the platform to improve the quality of life and accessibility of mental health services in Romania. 10. Medicai and Mircea Popa: Collaborative Medical Data Mircea Popa, through his involvement with Medicai, has been a key figure in the digitization of medical records and image sharing in Romania. Medicai provides a platform that allows patients and doctors to securely share and collaborate on medical images, reducing the reliance on physical media like CDs. Popa’s academic and professional activity through 2024 and 2025, including co-organising major IEEE conferences in intelligent engineering and medical cybernetics, demonstrates the deep scholarly roots of Romanian MedTech. 20 Future Romanian HealthTech and MedTech Leaders The "Innovator" Cohort: Emerging Leaders of 2026 The 2026 Romania Startup Awards nominated several early-stage companies that represent the next wave of HealthTech leadership. These entities focus on niche applications of DeepTech and specialised clinical needs. 11. Revelio Medical: Industrial MedTech Innovation Nominated as a "Healtech & Longevity Innovator," Revelio Medical is part of a new class of startups focusing on the industrial application of medical technology. While specific technical details are often proprietary at this stage, their nomination alongside giants like Synaptiq indicates a high degree of market validation and investor interest. 12. Medical Pilot: Clinical Workflow Optimisation Another ROTSA nominee, Medical Pilot, focuses on the "pilot" phase of healthcare delivery, optimising the initial interaction between patient data and clinical assessment. This startup addresses the critical need for more efficient triage and data-driven navigation within the Romanian healthcare system. 13. Nutribalance HealthTech: Personalising Nutritional Science Nutribalance HealthTech represents the convergence of nutrition and digital health. By using data-driven insights to manage metabolic health and longevity, the company aligns with the broader global trend toward preventative healthcare and "nutrition as medicine." 14. Brain Symphony: Neuro-Focused Therapeutics Nominated in the 2026 "Healtech & Longevity" category, Brain Symphony focuses on the complex field of neuroscience.Their work likely involves digital therapeutics or diagnostic tools designed to address cognitive decline and neurological performance, a sector of increasing importance as the European population ages. 15. Origin BCI: The DeepTech Frontier of Brain-Computer Interfaces Origin BCI is perhaps the most ambitious of the 2026 nominees, categorised under "Best DeepTech Startup". By developing brain-computer interfaces, the company is pushing the boundaries of how humans interact with medical hardware, potentially offering new solutions for patients with severe motor or neurological impairments. Financial Milestone Startup Amount / Stage Date Key Investors Largest Series C Dexory $165M Oct 2025 Atomico, Eurazeo, Lakestar Largest Debt Raise Databricks (Zaharia) $5B Jan 2025 Institutional Debt Top Series B Digitail $23M Nov 2025 Gradient Ventures, Partech EIC Grant dotLumen €11M 2025 EIC Fund Top Seed Round Orbotix €7M 2025 Bravo Victor VC Pre-Seed Biotech TCHC €500k 2024 Early Game Ventures Diaspora Leaders and Global Category Shapers The influence of Romanian talent extends far beyond the nation’s borders, with founders in the United States and Western Europe leading some of the most innovative HealthTech companies in the world. 16. Emi Gal and Ezra: Early Cancer Detection Emanuel "Emi" Gal, a serial entrepreneur from Bucharest, founded Ezra in 2018 with the mission of making full-body MRI cancer screening accessible. In May 2025, healthcare technology giants Function Health and Ezra announced their merger, with Function Health acquiring Ezra to integrate its MRI capabilities with lab-based health assessments. Gal’s trajectory, from his education in Applied Mathematics at Spiru Haret University to leading a global AI healthcare merger, serves as an inspiration for the entire Romanian tech community. 17. Valar Labs and the 30 Under 30 Influence The team at Valar Labs, including Romanian-linked founders featured in the Forbes 30 Under 30 Class of 2025 and 2026, represents the cutting edge of AI in oncology. Valar Labs uses AI to analyze tumor images to predict treatment response, helping patients find the most effective therapies. Their presence on international stages validates the high level of Romanian machine learning expertise on a global scale. 18. Etiq AI: Ensuring Ethical Algorithms in Healthcare While often categorized under General AI, Etiq AI’s focus on ethical machine learning has significant implications for HealthTech, where algorithmic bias can have life-or-death consequences. Nominated for "Excellence in Artificial Intelligence" at the 2026 Romania Startup Awards, the company provides the oversight necessary for medical AI companies like Synaptiq or Rayscape to deploy their technologies safely and fairly. 19. Kinderpedia: Paediatric Health and Communication Co-founded by Evelina Necula, Kinderpedia is an education and health management platform for children. While its primary market is EdTech, its role in pediatric health, tracking medical records, vaccinations and child development, makes it a critical leader in the "Healtech & Longevity" space. Their 2026 nomination for "Female-Led Startup of the Year" highlights the importance of integrated child-health management. 20. Parol: Automating the Clinical Record Parol is an emerging leader focused on automating medical documentation. By using AI to capture and structure patient-doctor interactions, Parol reduces the administrative burden on Romanian healthcare providers, allowing for more patient-centric care. The company was recognised as a "Best Fundraising Performer" in 2026, signalling strong investor confidence in its ability to solve a universal pain point in healthcare systems. Synthesis of Trends and Strategic Implications The collective data from these 20 leaders suggests several critical trends shaping the Romanian HealthTech and MedTech landscape through 2026. First, there is a definitive shift from "SaaS-only" solutions to "DeepTech and Hardware-Enabled AI". Startups like dotLumen and Dexory prove that Romania can compete in capital-intensive hardware manufacturing when it is paired with proprietary AI software. Second, the "Born Global" ethos has become the standard for Romanian founders. Companies like Digitail and The Cat Health Company target US and UK markets immediately, utilising Romania as a high-efficiency R&D hub while capturing higher-margin markets abroad. This strategy is supported by local venture capital firms like GapMinder, which manages a €45 Million fund, and Early Game Ventures, which recently launched a €60 Million Fund II specifically to back early-stage CEE innovators. Third, the emergence of longevity as a central theme, from feline studies (TCHC) to microbiome hacking (NostraBiome) and metabolic health (Nutribalance), indicates that Romania is moving beyond the management of acute illness toward the science of human healthspan extension. Conclusion: The Path Toward the Next Unicorn The Romanian HealthTech and MedTech sectors have moved beyond the experimental phase and are now in a period of aggressive scaling. The success of the 20 leaders profiled in this report, anchored by the record-breaking capital raises of 2025, suggests that the country’s first "HealthTech Unicorn" is imminent. The convergence of academic excellence, a high-performing engineering workforce, and a maturing investor ecosystem has created a resilient infrastructure for innovation. As these companies navigate regulatory submissions in 2026 and expand their clinical trials globally, they will not only bring prestige to the Romanian startup ecosystem but, more importantly, deliver transformative technologies to the global healthcare market. The transition from "Hackerville" to a "Global HealthTech Hub" is well underway, fuelled by a generation of founders who are as scientifically rigorous as they are entrepreneurially ambitious. Nelson Advisors > European MedTech and HealthTech Investment Banking   Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk Nelson Advisors regularly publish Thought Leadership articles covering market insights, trends, analysis & predictions @  https://www.healthcare.digital     Nelson Advisors publish Europe’s leading HealthTech and MedTech M&A Newsletter every week, subscribe today!  https://lnkd.in/e5hTp_xb    Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk #NelsonAdvisors   #HealthTech   #DigitalHealth   #HealthIT   #Cybersecurity   #HealthcareAI   #ConsumerHealthTech   #Mergers   #Acquisitions   #Partnerships   #Growth   #Strategy   #NHS   #UK   #Europe   #USA   #VentureCapital   #PrivateEquity   #Founders   #SeriesA   #SeriesB   #Founders   #SellSide   #TechAssets   #Fundraising   #BuildBuyPartner   #GoToMarket   #PharmaTech   #BioTech   #Genomics   #MedTech Nelson Advisors LLP   Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Nelson Advisors @ 2026 Events   Digital Health Rewired > March 2026 > Birmingham, UK    NHS ConfedExpo   >  June 2026 > Manchester, UK    HLTH Europe >  June 2026, Amsterdam, Netherlands   HIMSS AI in Healthcare  >  July 2026, New York, USA   Bits & Pretzels >  September 2026, Munich, Germany     World Health Summit 2026  >  October 2026, Berlin, Germany   HealthInvestor Healthcare Summit >  October 2026, London, UK  HLTH USA 2026 >  October 2026, USA   Barclays Health Elevate >  October 2026, London, UK    Web Summit 2026 >  November 2026, Lisbon, Portugal     MEDICA 2026 >  November 2026, Düsseldorf, Germany   Venture Capital World Summit > Toronto, Canada Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk

20 Future Irish HealthTech and MedTech Leaders The Republic of Ireland has established a formidable global position within the medical technology and digital health sectors, characterised by a unique synthesis of indigenous entrepreneurial agility and high-density multinational presence. As of 2025, the sector generates approximately €16 Billion in annual exports, representing 14% of the nation’s total export economy. With over 700 life sciences and health technology firms, more than 400 of which are homegrown, Ireland has successfully leveraged its academic research infrastructure and favourable venture capital environment to become the largest employer of MedTech professionals per capita in Europe. In 2024, the ecosystem reached a decade-high record in venture capital investment, securing €491.3 million across 89 deals, even as global life sciences funding experienced a dramatic contraction. This resilience is largely attributed to the maturing profile of the cluster, where late-stage and venture-growth deals now constitute 46% of total volume, reflecting a shift from speculative early-stage ventures to clinically validated, scalable platforms. This report analyses the twenty leaders and organisations at the vanguard of this evolution, examining the technological mechanisms, leadership backgrounds and market dynamics that define the next wave of Irish healthcare innovation. The Macro-Economic Foundations and Institutional Catalysts The trajectory of Irish MedTech leadership is inextricably linked to the state-supported infrastructure that de-risks innovation. The Disruptive Technologies Innovation Fund (DTIF), a €500 million vehicle administered by Enterprise Ireland, has been a critical engine for collaborative research, having awarded €298 million to 68 projects in the health and wellbeing sector to date. Investment and Deal Flow Maturity (2014-2025) The maturation of the Irish MedTech ecosystem is evidenced by the surging deal values and the increasing involvement of international Tier-1 investors. The following table delineates the capital flow and the pivot toward growth-stage financing. Metric 2014 Baseline 2024 Peak Performance 2025 Projected Outlook Total VC Investment €117.9 Million €491.3 Million Record Late-Stage Megadeals Total Deal Count 47 Deals 89 Deals Sustained High Activity Late-Stage Volume % 23% 46% Increasing Institutional Focus Key Sector Driver Early MedTech Prototypes AI & Interventional Platforms Integrated Home-Based Care This structural shift indicates that Ireland has moved beyond being a manufacturing hub for multinationals to becoming a primary source of intellectual property and clinical breakthroughs. The density of expertise in Galway, Dublin, and Cork has created a self-sustaining cycle where successful founders (e.g., those from Crospon or BiancaMed) reinvest their social and financial capital into the next generation of "spin-outs". 1. Conor Hanley (CEO, FIRE1): Redefining Chronic Disease Management Conor Hanley represents the archetype of the sophisticated Irish MedTech executive, combining deep technical training with international commercial experience. Hanley holds a PhD in Chemical Engineering and an MBA from INSEAD, having previously led BiancaMed through its acquisition by ResMed in 2011. As the CEO of FIRE1 (Foundry Innovation and Research 1), he oversees a Dublin-headquartered company that has secured one of the largest health tech rounds in Europe, a $120 Million late-stage financing in early 2025. The mechanism of FIRE1’s Norm™ system addresses the "proxy problem" in heart failure. Most current monitoring solutions rely on pressure proxies or indirect symptoms. In contrast, the Norm™ system utilises a sensor implanted in the inferior vena cava (IVC) to monitor fluid volume directly. The IVC is a highly compliant vessel and its diameter changes sensitively in response to small volume shifts that precede acute heart failure events. By measuring these dynamics, the system enables physician-directed self-management, allowing patients to adjust their own treatment at home and avoid hospitalisations that can cost the healthcare system upwards of $30,000 per visit. Under Hanley’s leadership, FIRE1 has received FDA Breakthrough Device Designation and is progressing toward a 2029 FDA approval target, a timeline supported by robust data from pivotal clinical trials. 2. Wayne Allen (CEO, Perfuze): Advancing the "First Pass" Gold Standard in Stroke Wayne Allen, CEO and co-founder of Galway-based Perfuze, leads a team that addresses the time-critical nature of ischemic stroke. Allen and co-founder Liam Mullins brought over 35 years of combined experience to the venture, identifying that less than 50% of current stroke patients achieve positive clinical outcomes due to the complexity of clot removal. Perfuze’s innovation lies in its Millipede88 Aspiration Catheter, which features a patented corrugated design. This engineering allows the "superbore" catheter to navigate the tortuous neurovascular anatomy without collapsing or losing its aspiration force at the clot face. In the MARRS (Millipede Aspiration for Revascularization in Stroke Study) pivotal trial, the device achieved a remarkable 77% First Pass Effect (FPE) for M1 occlusions. This is scientifically significant because the "first pass" is the primary predictor of positive patient recovery; every additional pass increases the risk of vessel damage and distal embolisation. With €22 million in Series A funding and recent FDA 510(k) clearance, Allen has positioned Perfuze for a limited market release in the US, supported by high-profile investors like EQT Life Sciences and Seroba. 3. Dr. Lucy O'Keeffe (CEO, CroíValve): Targeting the "Forgotten" Tricuspid Valve Dr. Lucy O’Keeffe is at the forefront of the structural heart revolution. As CEO of CroíValve, she leads a firm dedicated to treating tricuspid regurgitation, a condition where the heart's tricuspid valve fails to close properly, leading to backward blood flow and progressive heart failure. O’Keeffe, who holds a PhD in Biomedical Engineering and previously led R&D programs at Medtronic, has navigated CroíValve through the complex transition from concept to clinical stage. The DUO System developed by CroíValve is a minimally invasive coaptation heart valve device that repairs the tricuspid valve without surgery. This is critical for the vast majority of tricuspid patients who are currently considered too high-risk for open-heart procedures. The company is currently spearheading a €5.9 Million DTIF project to develop a solution suitable for over 90% of patients with this condition. O’Keeffe has strategically maintained a dual presence, with R&D and operations in Ireland and clinical/regulatory functions in the US, targeting a market opportunity estimated at over €3 Billion. 4. Jason Mowles (CEO, CergenX): The Convergence of AI and Neonatal Neurotechnology Jason Mowles transitioned from a senior career in banking and digital transformation to lead CergenX, a University College Cork (UCC) spin-out. Founded in 2021, CergenX leverages AI to solve a profound problem in neonatal care: the early detection of brain injury in newborns. Approximately five in every 1,000 babies suffer from some form of brain abnormality at birth, yet these injuries often remain undetected until developmental delays manifest years later. CergenX’s Wave device utilizes a vast databank of neonatal EEG signals, significantly different from adult brainwaves, to train algorithms that can perform a non-invasive screening in under 15 minutes. This technology democratizes neonatal neuro-assessment, as it does not require a resident neurologist to interpret the data. In 2025, Mowles oversaw the company’s receipt of FDA Breakthrough Device Designation and its acceptance into the TAP program, significant milestones for the company’s entry into the US and European markets. Under his leadership, the firm secured €6.7 Million from the DTIF, highlighting the strategic value of AI-driven diagnostics in the paediatric space. 5 & 6. John and Caroline O'Dea (Leaders, Palliare): Safety in the Modern Operating Room The husband and wife team of John and Caroline O’Dea are seasoned leaders within the Galway cluster. Having previously founded Crospon and sold it to Medtronic for $45 Million in 2017, they launched Palliare in 2018 as a spin-out focused on surgical safety. John O’Dea, a PhD in Electronics Engineering and past President of Engineers Ireland, serves as Group CEO, while Caroline O’Dea manages the Irish operations. Palliare’s flagship innovation, the EVA15 insufflator, addresses the hazardous buildup of surgical smoke during laparoscopic and robotic procedures. Surgical smoke contains aerosolized biological matter and chemical byproducts that pose long-term health risks to medical staff. The EVA15 system combines continuous pressure insufflation with integrated smoke evacuation, ensuring a clear visual field for surgeons and a safer environment for the team. Palliare was crowned Emerging Medtech Company of the Year at the 2025 Irish Medtech Awards, a recognition of its turnover doubling annually since 2022 and its successful US market launch. 7. Dr. Elizabeth McGloughlin (Co-Founder, Tympany Medical): Revolutionizing ENT Imaging Dr. Elizabeth (Liz) McGloughlin embodies the transition from clinical practice to high-tech entrepreneurship. A former doctor in anaesthesia and critical care, she identified a workflow bottleneck during her BioInnovate fellowship: surgeons must frequently remove and clean endoscopes during procedures, disrupting their focus and extending surgery times. Tympany Medical, based in Galway, developed the Solascope, a variable-angle, self-cleaning endoscope specifically designed for ENT (ear, nose, and throat) procedures. By utilising "chip-on-tip" CMOS sensors, the Solascope allows for high-resolution imaging and real-time angle adjustment without withdrawing the device. McGloughlin, recognised as a finalist for the 2025 European Prize for Women Innovators, has expanded the team to include experts in optical physics and miniaturised electronics, securing over €3.5 Million in seed funding to advance toward FDA certification. 8. Donal O'Shea (CEO, Deciphex): Scaling Digital Pathology Globally Donal O’Shea, the CEO and founder of Deciphex, is transforming the traditionally analog field of histopathology. Based in Dublin, Deciphex addresses the global shortage of pathologists by offering the Diagnexia platform, which connects hospitals to a network of over 250 subspecialty pathologists. This allows for rapid diagnostics and the reduction of surgical backlogs that have plagued healthcare systems post-pandemic. Under O’Shea’s guidance, Deciphex has grown to over 220 employees and raised €15 million in venture debt in late 2025 to accelerate its US expansion. The company’s secondary focus involves AI-driven clinical medication safety systems, which use diagnostic decision-support tools to identify risks in colorectal screening. Deciphex won the Collaboration in Medtech Award at the 2025 Irish Medtech Awards, underscoring its success in integrating AI into the clinical workflow across multiple international markets. 9. Dr. Alison Liddy (CEO, Relevium Medical): Disrupting the Osteoarthritis Market Dr. Alison Liddy leads Relevium Medical, a University of Galway spin-out that targets the "hidden disability" of knee osteoarthritis (OA). Liddy, who holds a PhD in Biochemical Engineering and previously worked at Boston Scientific and Roche, developed RM-010, an injectable gel-based therapeutic. The technological insight behind RM-010 is the controlled release of capsaicin. While capsaicin is a powerful pain blocker, its raw application causes intense burning. Relevium’s delivery system gradually releases the compound into the knee joint at concentrations below the threshold for burning pain but high enough to achieve nerve ablation for up to six months. This offers a superior alternative to steroids, which can advance joint disease, and hyaluronic acid, which often lacks efficacy. Liddy secured €4.6 Million in DTIF funding in 2024 and is currently raising a €10 Million Series A to fund clinical trials, positioning the company to capture a share of a market opportunity estimated at $7.7 Billion. 10. Tom Fitzmaurice (CEO, LaNua Medical): Modernizing Embolization Procedures Tom Fitzmaurice, a former Vice President at Medtronic, is the CEO of LaNua Medical, a NovaUCD spin-out founded in 2024. LaNua addresses the risks associated with embolisation, a procedure where blood flow is intentionally blocked to treat tumours or bleeding. Traditional embolisation can carry risks of reflux, where the blocking agent travels to non-target areas. LaNua’s flagship device, ECORE™, is an umbrella-shaped occlusive barrier that is deployed deep within blood vessels to form a precise barrier. Fitzmaurice led the company to win the 2024 Enterprise Ireland Big Ideas competition and secured a €6 million seed round. The company is currently collaborating with Integer Holdings to clinically validate ECORE™ across a wide range of vessel sizes, aiming to reduce hospital costs and procedure times for interventional radiologists. 11. Judi O'Malley (CEO, Spiorad Medical): Closing the Gap in Cardiovascular Access Judi O’Malley, CEO and co-founder of Spiorad Medical, brings extensive clinical and commercial expertise to the cardiovascular field. A former vascular physiologist with the HSE and a sales manager for multinationals like Medtronic and Abbott, she identified a critical unmet need for efficient large-bore vascular closure devices. Spiorad’s focus is on the safety of procedures such as TAVI (Transcatheter Aortic Valve Implantation), which require large incisions in the femoral artery. O’Malley founded Spiorad alongside interventional cardiologist Dr. Samer Arnous to create devices that make closure easier for physicians and safer for patients. In 2025, the company secured a €1.7 million DTIF award, allowing it to accelerate the development of advanced cardiovascular support solutions. Spiorad’s presence in the University of Galway’s Business Innovation Centre highlights the strong regional support for female-led MedTech ventures. 12. Brian Shields (CEO, Neurent Medical): Neurostimulation for Chronic Rhinitis Brian Shields is the CEO and founder of Neurent Medical, a Galway-based company that has developed a breakthrough treatment for chronic rhinitis. Shields, a former management consultant and BioInnovate fellow, led the company through several financing rounds to bring its Neuromark™ product to the US market. Chronic rhinitis is characterised by an overactive autonomic nervous system in the nasal cavity. Neurent’s technology uses a handheld probe to apply targeted neurostimulation, disrupting the nerves that cause persistent nasal discharge and congestion. In early 2026, Neurent closed an oversubscribed €62.5 Million Series C round led by MVM Partners. Shields has been instrumental in building an international team and establishing a strategic partnership with Northwell Health, ensuring that Irish-developed neuro-clinical solutions have a clear commercialisation pathway in the US. 13. Aaron Hannon (CEO, Luminate Medical): Enabling In-Home Cancer Care Aaron Hannon, co-founder and CEO of Luminate Medical, represents the new generation of Irish leaders focused on patient-centered "at-home" care. Co-founding the company at 19 with Dr. Barbara Oliveira and Professor Martin O’Halloran, Hannon has developed a mission to deliver every cancer treatment in the patient’s home. Luminate’s wearable medical devices mitigate the side effects of chemotherapy, such as hair loss and peripheral neuropathy. The company raised $15 Million in a Series A round in late 2024 to advance its first-in-patient clinical trials. Hannon’s leadership has been recognised by several awards, including the 2022 EIT Health Catapult Audience Choice Award, and the company has expanded from its initial trio of founders to a team of 14 as it prepares for large-scale US trials. 14. Aidan Crawley (CEO, Amber Therapeutics): Precision Neuromodulation for Bladder Control Aidan Crawley is the CEO and co-founder of Amber Therapeutics, a company developing bioelectrical therapies for peripheral nervous system disorders. Crawley founded the company while serving as an Entrepreneur-in-Residence at Oxford Science Enterprises, partnering with world-class scientists to address the problem of urinary incontinence. Amber’s Picostim™ system is the first fully implantable, closed-loop neuromodulation therapy for mixed urinary incontinence. By targeting the pudendal nerve, the system can both sense physiological responses and provide dynamic stimulation to restore natural bladder function. Crawley, whose background includes a career at Goldman Sachs and the growth-stage US firm Addepar, has led the company through successful AURA-2 and AURA-3 studies. In 2025, Amber established a headquarters within a validated manufacturing facility to execute its US-European pivotal trial at scale. 15. Grace O'Donnell (CEO, Phyxiom): Digital Transformation of Respiratory Care Grace O’Donnell, CEO and co-founder of Phyxiom, leads a digital health spin-out from RCSI that targets the mismanagement of asthma and COPD. Co-founded with Professor Richard Costello, Phyxiom leverages a decade of clinical research and patented algorithms to provide a device-independent analytics platform. The Phyxiom platform integrates data from smart inhalers and spirometry devices, providing physicians with an intelligent decision-support system. This supports more accurate diagnoses and ensures that patients adhere to medication protocols, potentially saving payers up to $13.5 Billion annually in the US alone. O’Donnell and her team completed a seed funding round in mid-2025 and are currently live across 13 HSE asthma clinics, with expansion plans for the UK in 2026 and the US in 2027. 16. Seamus Fahey (CEO, ICS Medical Devices): Leading the Irish CDMO Surge Seamus Fahey is the CEO and founder of ICS Medical Devices, a contract design and manufacturing organization (CDMO) that has become a vital partner for global start-ups. Fahey, with 27 years of experience including a senior role at Creganna Medical, established ICS in 2019 to provide world-class catheter solutions. ICS Medical Devices has grown rapidly, opening a new facility in Galway and announcing the creation of 72 new jobs in 2025 to support its international expansion into Asia and the Middle East. The company’s success reflects the broader trend in Ireland where technical expertise in catheter manufacturing is being commercialized as a high-value service. ICS was a finalist for Emerging Medtech Company of the Year and Medtech Partner/Supplier of the Year at the 2025 Irish Medtech Awards. 17. Martina Skelly (CEO, Yellow Schedule): AI for Patient Flow Efficiency Martina Skelly is the co-founder and CEO of Yellow Schedule, one of the primary winners of the HIHI.AI 2025 call. Her company’s Triage Link system uses AI to automate the clinical triage process, improving patient flow and reducing bottlenecks in hospital outpatient departments. Skelly’s leadership represents the application of AI to operational healthcare challenges. By ensuring solutions are "trustworthy and human-centered," Yellow Schedule aligns with the Irish national AI strategy. The pilot programs facilitated by Health Innovation Hub Ireland will allow Skelly to clinically validate the efficiency gains and patient experience improvements generated by her AI-powered triage platform. 18. Andrew Glass (CEO, Vivasure Medical): Pioneering Large-Bore Vascular Closure Andrew Glass has led Vivasure Medical through one of the most successful exits in recent Irish MedTech history. As CEO, he oversaw the development of PerQseal Elite, a fully absorbable, suture-less vascular closure device. In January 2026, Vivasure was acquired by Haemonetics for €185 million, a testament to the company’s progress in advancing large-hole closure technology. The technology behind Vivasure uses a synthetic polymer implant to provide high-integrity closure for the large-bore arterial incisions required in structural heart and endovascular procedures. Glass, who brought a background in international MedTech leadership to the firm, has noted that joining Haemonetics provides the global scale necessary to make PerQseal Elite available to physicians and patients worldwide. 19. Brian Thornes (CEO, X-Bolt Orthopedics): Surgical Innovation in Fragile Bone Dr. Brian Thornes, an orthopedic surgeon and founder of X-Bolt Orthopedics, has developed a revolutionary solution for hip fracture fixation in elderly patients. Thornes, also the inventor of the TightRope® treatment for ankles, founded X-Bolt to address the clinical failure of traditional lag screws in osteoporotic (fragile) bone. X-Bolt’s expanding technology provides a stronger anchor in the femoral head than traditional screws, significantly reducing reoperation rates. The Pro-X1 trochanteric nailing system received FDA clearance in 2023 and launched commercially in the US in 2024. Thornes’ ability to translate a "lightbulb moment" (observing domestic wall anchors in his apartment) into a patented medical device highlights the role of clinical observation in driving MedTech innovation. 20. Susan Treacy (CEO, HealthTech Ireland): Strategic Leadership and Policy Advocacy Susan Treacy, while not a startup founder, is arguably the most influential leader shaping the future of Irish HealthTech.Since becoming CEO of HealthTech Ireland in 2021, she has led the organization through a period of strategic transformation, including the delivery of a Memorandum of Understanding with the HSE. Treacy serves as the only industry representative on the HSE AI Implementation Group and participates in HIQA working groups on AI and Health Technology Assessment (HTA). She was named Winner of the Women in STEM Award in the Health Technology category at the 2025 Business Post Awards. Her role is vital in ensuring that industry perspectives are embedded in national health strategy, providing the policy framework that allows innovators like Mowles and O’Donnell to scale their technologies within the Irish and international markets. Structural Analysis of Leadership Origins The twenty leaders analyzed in this report do not exist in isolation; their success is a product of the "Innovation with Impact" strategic pillar of the Irish government. The following table summarises the origins and developmental support for these leaders. Origins of the Future Leaders Leader Organization Origin/Incubator Key Funding/Support Conor Hanley FIRE1 The Foundry (Silicon Valley) $120M Megadeal Lucy O'Keeffe CroíValve Medtronic Alumna €5.9M DTIF Award Jason Mowles CergenX UCC / INFANT Centre €6.7M DTIF Award Liz McGloughlin Tympany Medical BioInnovate Ireland €3.5M Seed Round Alison Liddy Relevium Medical University of Galway €4.6M DTIF Award Brian Shields Neurent Medical BioInnovate Ireland €62.5M Series C Aidan Crawley Amber Therapeutics Oxford Science Enterprises US Pivotal Trial Support Tom Fitzmaurice LaNua Medical NovaUCD €6M Seed Funding The Role of BioInnovate Ireland BioInnovate Ireland, founded by the late Ian Quinn and currently led by Professor Martin O’Halloran, is the single most influential program for training this new cohort of leaders. Affiliated with Stanford Biodesign, the program has trained 159 fellows to date, with approximately half progressing to lead their own startups. As of 2025, BioInnovate startups have generated €84 Million in wages and supported 1,460 jobs in Ireland, creating a Gross Value Added (GVA) of €277 Million. The program focuses on solving real-world clinical challenges through a 10-month intensive bootcamp and hospital immersion process. Technological Trajectories and Second-Order Insights A second-order analysis of the Irish MedTech landscape reveals a significant shift away from hardware-only devices toward integrated platforms that combine mechanics, optics, and AI. The Shift Toward Software-as-a-Medical-Device (SaMD) Firms like CergenX and Phyxiom are leading a transition where the primary value resides in the algorithm rather than the sensor. This requires a fundamental shift in regulatory strategy, moving away from 510(k) clearances for physical devices toward "Breakthrough Designations" for AI software. The implication for future leaders is a need for dual expertise in both clinical medicine and data science, a combination exemplified by Jason Mowles’ transition from banking to neonatal neurotechnology. The Proximity of Multinationals and Spin-Outs The presence of nine of the world's top ten MedTech multinationals in Ireland (e.g., Medtronic, Boston Scientific, Stryker) provides a "training ground" for future entrepreneurs. Leaders like Lucy O’Keeffe (Medtronic), Tom Fitzmaurice (Medtronic), and Seamus Fahey (Creganna) utilize their "MNC pedigree" to build startups that are designed for acquisition from day one. This created a "ripple effect" where the exit of one company (Crospon, Vivasure) immediately fuels the creation of several more through the recycling of leadership talent. The Democratisation of Complex Diagnostics AI is being used to move complex assessments from the specialist clinic to the bedside or home. CergenX’s ability to screen for brain injury without a neurologist and Phyxiom’s remote asthma monitoring represent a broader trend of "de-skilling" diagnostic interpretation, thereby increasing access and lowering costs. This is particularly relevant in the US market, where hospital-based care is increasingly being replaced by home-based management models. Conclusions and Future Outlook The Irish MedTech and HealthTech landscape from 2024 to 2026 is defined by a level of maturity that allows for sustained global impact. The combination of seasoned serial entrepreneurs (The O'Deas, Thornes, Hanley) and a structured innovation pipeline (BioInnovate, CÚRAM, NovaUCD) ensures that Irish firms are no longer merely manufacturing components but are defining global clinical standards. The strategic focus on AI-driven diagnostics, minimally invasive structural heart repairs, and bioelectrical therapeutics aligns perfectly with global healthcare trends toward efficiency, safety, and personalized care. Furthermore, the massive influx of late-stage capital and the formalization of US clinical pathways through partnerships with health systems like Northwell Health provide the necessary "runway" for these firms to reach commercial maturity. As Ireland continues to punch above its weight in the global sector, these twenty leaders will likely remain at the center of the most significant healthcare acquisitions and clinical breakthroughs for the remainder of the decade. Nelson Advisors > European MedTech and HealthTech Investment Banking   Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk Nelson Advisors regularly publish Thought Leadership articles covering market insights, trends, analysis & predictions @  https://www.healthcare.digital     Nelson Advisors publish Europe’s leading HealthTech and MedTech M&A Newsletter every week, subscribe today!  https://lnkd.in/e5hTp_xb    Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk #NelsonAdvisors   #HealthTech   #DigitalHealth   #HealthIT   #Cybersecurity   #HealthcareAI   #ConsumerHealthTech   #Mergers   #Acquisitions   #Partnerships   #Growth   #Strategy   #NHS   #UK   #Europe   #USA   #VentureCapital   #PrivateEquity   #Founders   #SeriesA   #SeriesB   #Founders   #SellSide   #TechAssets   #Fundraising   #BuildBuyPartner   #GoToMarket   #PharmaTech   #BioTech   #Genomics   #MedTech Nelson Advisors LLP   Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Nelson Advisors @ 2026 Events   Digital Health Rewired > March 2026 > Birmingham, UK    NHS ConfedExpo   >  June 2026 > Manchester, UK    HLTH Europe >  June 2026, Amsterdam, Netherlands   HIMSS AI in Healthcare  >  July 2026, New York, USA   Bits & Pretzels >  September 2026, Munich, Germany     World Health Summit 2026  >  October 2026, Berlin, Germany   HealthInvestor Healthcare Summit >  October 2026, London, UK  HLTH USA 2026 >  October 2026, USA   Barclays Health Elevate >  October 2026, London, UK    Web Summit 2026 >  November 2026, Lisbon, Portugal     MEDICA 2026 >  November 2026, Düsseldorf, Germany   Venture Capital World Summit > Toronto, Canada Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk

20 Future Polish HealthTech and MedTech Leaders The Polish healthcare technology ecosystem has transitioned from a localised secondary market into a primary driver of European deep-tech innovation as of the first quarter of 2026. This transformation is underpinned by a structural shift from traditional software development to the application of advanced artificial intelligence, multimodal biological simulations, and high-precision medical hardware. Currently, Poland hosts over 3,300 active startups, with the Warsaw and Kraków hubs serving as the principal gravity centers for venture activity and technical talent. The sector's expansion is validated by significant capital inflows; in 2025, venture capital investment reached approximately PLN 3.4 Billion (~EUR 800 Million) across 180 distinct transactions, a momentum that has rallied into the current fiscal year. The institutional backbone of this growth is reinforced by the launch of "Future Tech Poland," a €350 Million fund-of-funds initiative spearheaded by the European Investment Fund (EIF) and Bank Gospodarstwa Krajowego (BGK). This program provides critical liquidity for high-tech ventures at various stages of growth, emphasizing the Polish government’s commitment to establishing the nation as a global tech hub and enhancing the competitiveness of the European Union’s fifth-largest economy. Within this fertile landscape, a cadre of twenty leaders and their respective organizations have emerged as the vanguard of the Polish HealthTech and MedTech renaissance. The Pillars of Digital Health Infrastructure The first category of leadership focuses on the foundational layers of the medical experience, scheduling, triage, and data interoperability. These figures have successfully navigated the transition from initial digital adoption to building core infrastructure that integrates directly into the global healthcare stack. 1. Mariusz Gralewski and the DocPlanner Global Network Mariusz Gralewski, the founder and CEO of DocPlanner, remains the preeminent figure in the Polish digital health landscape. Since its inception in 2012, DocPlanner has evolved from a simple doctor-review platform (ZnanyLekarz) into a global digital health network that links millions of patients with medical professionals across multiple continents. Gralewski’s strategic vision focused on international market expansion, leading to the acquisition of platforms such as Doctoralia, MioDottore and ClinicCloud, thereby creating a unified ecosystem for patient management. As of late 2024, the DocPlanner group reported over 30 million monthly unique visitors and nearly 5 million monthly appointments managed through its various interfaces. The company’s financial trajectory, characterised by a total raise exceeding $240 million and a recent Series E valuation, positions it as a veteran leader in the Polish unicorn landscape. Gralewski's impact extends beyond mere scheduling; by centralising patient data and doctor-patient interactions, he has established a standardised digital layer that reduces administrative friction for over 1,300 employees and thousands of clinical partners worldwide. 2. Piotr Orzechowski and the AI Triage Standard at Infermedica Piotr Orzechowski, through Infermedica, has pioneered the use of artificial intelligence in medical triage and clinical decision support. The "computer brain" developed under his leadership serves as a diagnostic engine that guides patients and clinicians through the complexities of health symptomatic analysis. Infermedica’s B2B SaaS model has gained international traction, notably through a strategic partnership with Microsoft and successful expansion into the German and U.S. markets. In 2022, the company secured $30 million in Series B funding led by investors such as Karma Ventures and Inovo Venture Partners, reflecting a deep industry confidence in its AI-native architecture. Orzechowski’s focus on integrating smart programs into the quiet "background" of hospital routines allows clinics to improve patient visit quality without disrupting existing workflows. This focus on non-intrusive integration is a key characteristic of the second-order evolution in Polish HealthTech, where technology is seen as a supportive partner rather than a disruptive burden to the clinician. 3. Robert Lugowski and the Real-Time Data Revolution of CliniNote Robert Lugowski, as CEO of CliniNote, addresses one of the most persistent bottlenecks in modern healthcare: the structuring and utilization of clinical data. Founded in 2020, CliniNote utilizes Natural Language Processing (NLP) to "unlock" the power of clinical data by structuring it in real-time as medical professionals enter notes into existing Hospital Information Systems (HIS) and Electronic Health Records (EHR). This innovation addresses the massive inefficiencies in clinical data management, which traditionally require manual processing and significant administrative time. The CliniNote platform, developed in collaboration with clinicians from the National Institute of Oncology in Warsaw, includes modules like the CliniNote Assistant and DataCollector, which are designed to support pharmaceutical companies and Contract Research Organizations (CROs). The company’s strategic growth was accelerated by its 2023 funding round led by Sunfish Partners, enabling its solutions to be implemented in major European projects such as Idea4RC and DigiOne. Lugowski’s leadership represents a critical shift toward data-driven decision-making, where the "exhaust" of clinical encounters is converted into high-quality, interoperable data for research and drug development. 4. Marta Lacka and the Strategic Data Insights of Quantia While many HealthTech founders focus on the patient-provider interaction, Marta Lacka, CEO and founder of Quantia, addresses the data visibility gap for consumer healthcare brands. Quantia is an AI-driven e-commerce data platform that provides real-time insights into market dynamics, including product availability, pricing, and sales performance for enterprise-level retail and health brands such as Nespresso and Procter & Gamble. In May 2024, Quantia secured $1.2 Million in pre-seed funding led by Inovo.vc and Team X. Lacka’s leadership is defined by her "enterprise-first" background, allowing Quantia to compress strategic planning cycles that typically take ten working days into just 3-5 minutes. By ensuring that both brands and retailers have equal access to performance data, Quantia drives category growth and ensures the right medical and wellness products are available to consumers when needed. DeepTech and the Future of Pharmaceutical Simulation The second tier of Polish leadership operates at the intersection of biology and computation, aiming to resolve the high failure rates and astronomical costs associated with traditional drug development and synthesis. 5. Piotr Surma and the Generative Simulation of Ingenix.ai Piotr Surma, co-founder and CEO of Ingenix.ai , is perhaps the most prominent representative of the "AI-native" wave in Polish MedTech. Surma, who previously co-founded Applica (an AI firm acquired by Snowflake), launched Ingenix in 2023 alongside Adam Dancewicz to address the 90% failure rate of pilot drugs. The startup recently secured €9 Million in seed funding, led by Inovo.vc with participation from OTB Ventures and the IFC—to develop a multimodal generative AI co-pilot that simulates clinical trials with unprecedented granularity. The Ingenix platform utilizes "digital twins" and is trained on diverse multimodal datasets, including genomic, transcriptomic, and imaging inputs. By simulating biological processes from the molecular level through cellular, tissue, and population-level analysis, the system predicts clinical endpoints and potential adverse events before a physical trial begins. Surma’s vision is to make the drug development process predictable, potentially delivering the "GPT moment" for the pharmaceutical sector and significantly reducing the $50 billion annual global investment in clinical trials. 6. Piotr Byrski and the Retrosynthesis AI of Molecule.one Piotr Byrski and Paweł Włodarczyk-Pruszyński, founders of Molecule.one , identified a fundamental bottleneck in drug discovery: the manufacturing feasibility of hypothetical compounds. Molecule.one ’s proprietary AI uses retrosynthesis to identify cost-efficient and chemically sound pathways for synthesising new compounds, effectively working backward from a desired molecule to available elements. Founded in 2016 during the founders' medical studies in Warsaw, Molecule.one closed a $4.6 million seed round in 2021.The company’s SaaS model provides pharmaceutical companies with predictive informatics that suggest optimal reaction conditions and score hypothetical synthesis pathways. By unlocking "digital chemistry," Byrski’s team allows for the exploration of previously inaccessible structures, accelerating the development of innovative drugs to meet emerging health challenges. Startup Leader Core Innovation Key Funding / Investors Ingenix.ai Piotr Surma Multimodal AI simulations for clinical trials €9M Seed / Inovo.vc , OTB, IFC Molecule.one Piotr Byrski AI-driven retrosynthesis and drug discovery $4.6M Seed / Atmos Ventures, Sunfish Partners CliniNote Robert Lugowski Real-time NLP for medical data structuring Seed / Sunfish Partners Quantia Marta Lacka AI e-commerce analytics for health brands $1.2M Pre-Seed / Inovo.vc , Team X Cardiovascular Innovation and High-Precision Hardware Hardware-enabled medical technology in Poland is witnessing a resurgence, led by founders who combine surgical experience with advanced materials science. 7. Professor Paweł Buszman and the i4hv Longevity Initiative The startup i4hv, led by interventional cardiologists including Professor Paweł Buszman (Medical Director) and Dr. Piotr Hirnle, is developing a biological heart valve with a significantly extended lifespan. Standard biological valves typically last 10–15 years, necessitating repeat high-risk surgeries for patients over their lifetime. i4hv’s innovation uses polymer or transgenic biological materials to extend this lifespan to 20–30 years. The project, which received over PLN 30 Million in funding from the European Funds for a Modern Economy (FENG), focuses on Transcatheter Aortic Valve Implementation (TAVI). This minimally invasive, percutaneous therapy is traditionally reserved for older patients; however, i4hv’s long-lasting valves aim to make the procedure accessible to younger patients in their 40s and 50s, allowing them to maintain active lives without the threat of frequent repeat surgeries. 8. Dr. Honorata Hafke and the Remote Diagnostics of StethoMe Dr. Honorata Hafke founded StethoMe to bridge the gap between home-based monitoring and professional diagnostic accuracy. StethoMe has developed a wireless, AI-powered stethoscope that enables parents and patients to conduct lung and heart examinations from home. The device identifies abnormalities in breath sounds and provides immediate feedback through a consumer-friendly interface, while also sharing high-quality audio data with medical professionals for remote triage. StethoMe’s trajectory is defined by its partnerships with tech giants like Amazon Web Services and Nvidia, which support its AI development. Having secured $2.5 million in Series A funding from investors like TDJ Pitango Ventures and Movens VC, StethoMe represents a shift toward "decentralised diagnostic hubs" that alleviate the burden on paediatric and primary care clinics. The Rise of the Polish Femtech Sector Femtech has emerged as a particularly high-growth vertical in Poland, with fifteen innovative startups identified as changing the landscape of women's health through AI, specialised hardware, and community-driven care. 9. Michał Matuszewski and the AILIS Breast Health System Michał Matuszewski is the originator and CEO of AILIS, which has developed the world's first AI-powered breast health monitoring capsule. The system uses Parametric Dynamic Imaging (PDI) to distinguish areas of increased activity from normal tissue, identifying cancerous lesions at a very early stage where the recovery rate is up to 99%. Matuszewski’s vision centers on a "fee-for-health" model, transitioning breast screening from hospitals to accessible locations like shopping malls and offices. AILIS's methodology is non-invasive, radiation-free, and painless, allowing for frequent examinations without the health risks associated with traditional mammography. The company has collaborated with more than 100 experts over seven years and is currently conducting clinical trials with the National Oncology Institute in Kraków. The design of the AILIS capsule, which won the Red Dot Award, emphasizes a "woman-centric" sensory experience to reduce the psychological stress associated with medical screenings. 10. Ula Sankowska and the IVF Optimization at MIM Fertility Ula Sankowska and PhD Piotr Wygocki founded MIM Fertility to revolutionize the reproductive medicine sector using artificial intelligence. The startup’s software platforms, EMBRYOAID and FOLLISCAN, assist IVF doctors and embryologists by automating the grading of embryos and the measurement of ovarian follicles. These tools significantly increase success rates while reducing the time and costs associated with fertility procedures. MIM Fertility originated from the Faculty of Mathematics, Informatics, and Mechanics at the University of Warsaw, highlighting the critical link between academic research and commercial MedTech in Poland. In December 2023, the startup raised $2 million in seed funding from Tangent Line and Peleton to expand its global presence. Their recent research presented at ASRM 2025 demonstrates that their AI models match the accuracy of expert sonographers in follicle measurement, validating the clinical utility of their algorithms. 11. Kaja Rybicka-Gut and the Transparency of Your KAYA Kaja Rybicka-Gut, co-founder of Your KAYA, has led the charge in the organic intimate health and care sector. Your KAYA operates on a subscription model, offering organic cotton menstrual products that emphasize health safety and environmental sustainability. While categorised as an e-commerce brand, Rybicka-Gut has used the platform to build a comprehensive wellness ecosystem that provides education on women's health, representing the intersection of HealthTech and consumer empowerment. 12. Aleksandra Staniszewska and the Precision of My OVU Aleksandra Staniszewska is the creator of My OVU, an innovative ovulation thermometer that utilizes a vaginal silicone disc for precise cycle monitoring. By combining specialized hardware with an AI-integrated app, My OVU provides women with accurate data on fertile days and overall hormonal health. This approach reflects the broader trend of "miniaturized medical labs" where hardware-software integration allows for diagnostic-level monitoring outside of clinical settings. 13. Karolina Szymczak-Adamczyk and the EndoMe Community Karolina Szymczak-Adamczyk founded EndoMe to support women struggling with endometriosis, drawing from her decade-long struggle with the disease. EndoMe combines a supplement brand with a supportive community, addressing the holistic needs of patients who often face long diagnostic delays and inadequate support in traditional health systems. Szymczak-Adamczyk’s leadership highlights the importance of "patient-led innovation," where lived experience dictates the design of health solutions. Femtech Startup Leader Focus Area Technology / Approach AILIS Michał Matuszewski Breast Cancer Detection Parametric Dynamic Imaging (PDI) + AI MIM Fertility Ula Sankowska Infertility Treatment EMBRYOAID (Embryo grading) + FOLLISCAN My OVU Aleksandra Staniszewska Fertility Monitoring Vaginal silicone disc + AI app EndoMe Karolina Szymczak-Adamczyk Endometriosis Support Specialized supplements + Community Your KAYA Kaja Rybicka-Gut Intimate Care Subscription-based organic products Primary Care, Wellness and Mental Health A new generation of Polish HealthTech leaders is redefining the "front door" of healthcare, moving beyond episodic treatment to continuous wellness management and integrated primary care. 14. Adam Janczewski and the Hybrid Model of Jutro Medical Adam Janczewski, founder of Jutro Medical, has pioneered a hybrid model that combines advanced digital triage with a network of modern physical clinics. Founded in 2020, Jutro Medical aims to revolutionise primary healthcare (POZ) accessibility in Poland by automating administrative tasks and offering seamless telemedicine integrations. In 2024, the startup secured debt financing from mBank to fuel its physical expansion. Janczewski’s model addresses the chronic underfunding and administrative bloat of traditional primary care, offering a blueprint for a more efficient, patient-centred public-private health integration. 15. Dominik Swadzba and the Diagnostic Access of uPacjenta Dominik Swadzba founded uPacjenta in 2021 to promote preventive laboratory testing among Poles. The company utilizes a B2B, B2C, and marketplace business model to offer at-home blood collection services, making diagnostic testing more accessible and less time-consuming. By lowering the barriers to regular health monitoring, uPacjenta facilitates early intervention and supports the broader shift toward proactive health management. The startup secured nearly €4.7 million in seed funding, underscoring the market's demand for decentralised diagnostic services. 16. Jakub Zielinski and the Mental Wellness Platform Mindgram Jakub Zielinski founded Mindgram in 2021 as a comprehensive science-based platform for mental wellness in the workplace. Mindgram provides employees with access to psychologists, psychotherapists, and mental health resources through a mobile app. The company secured $7.7 million in seed funding led by Market One Capital, reflecting the rapid prioritisation of mental health as a core component of corporate wellness and HealthTech infrastructure. 17. Piotr Sosnowski and the Metabolic Focus of Holi Piotr Sosnowski and Kuba Koziej are the leaders behind Holi, a HealthTech startup dedicated to metabolic health management. Holi provides a structured treatment process that integrates medical monitoring, e-prescriptions, and educational resources, particularly focusing on the rising demand for obesity management and metabolic optimisation. With over 2,500 patients served and €3.5 Million in funding, Holi represents the "TechBio" approach to chronic disease management, where software serves as the delivery mechanism for complex medical protocols. 18. Patrycja Brzozowska and the Personalized Protocols of Mos Health Patrycja Brzozowska, alongside co-founders Paweł Chrzan and Paweł Sobkowiak, launched Mos Health to deliver personalised health protocols through an AI-driven platform. Mos Health analyzes user-provided data, lab results, and wearable device data to generate interventions focused on energy, sleep, and nutrition. In early 2026, the Polish-American company raised $1.1 million in a pre-seed round led by SMOK Ventures and Movens Capital. Brzozowska’s goal is to build a "digital partner" that guides users step-by-step through health optimizations, initially targeting the U.S. and Polish employer benefit markets. 19. Michał Kaczor and the Software Benchmarking of Gralio.ai Michał Kaczor, CEO and co-founder of Gralio.ai , is building a critical infrastructure tool that assists medical and business professionals in navigating the increasingly complex HealthTech software market. Gralio.ai uses AI models and web bots to analyze thousands of product reviews and user experiences, creating impartial, "apples-to-apples" comparisons of software tools. As HealthTech becomes "bedrock infrastructure," Kaczor’s platform ensures that healthcare providers can find, compare, and choose the right AI-driven tools for their unique needs, bringing order to a chaotic marketplace. 20. Michal Czyz and the Respiratory Management of FindAir Michal Czyz founded FindAir in 2016 to digitize the management of asthma and COPD. FindAir’s smart inhaler devices and mobile app provide patients and doctors with real-time data on medication usage and environmental triggers. By combining IoT hardware with sophisticated data analytics, Czyz has created a system that improves patient compliance and allows for more precise adjustments to treatment plans, representing the future of "connected respiratory care". Market Context and Structural Dynamics The individual successes of these 20 leaders are part of a broader "tale of two markets" occurring within the Polish and European digital health space. On one hand, AI-native upstarts like Ingenix and AILIS are attracting substantial rounds at unprecedented speeds; on the other, established players are becoming the "core infrastructure" that incumbents rely on to navigate digital transformation. Venture Capital and Institutional Support The funding landscape for Polish HealthTech is increasingly characterized by "mega-deals" and the entry of global "Goliath" investors such as Andreessen Horowitz and General Catalyst into the broader European market. Locally, funds like Inovo.vc , OTB Ventures, and Market One Capital have been instrumental in backing the current generation of leaders. Entity Role Impact on HealthTech Future Tech Poland €350M Fund-of-Funds Provides liquidity for early and growth-stage tech startups. Inovo.vc Early-stage VC Lead investor in Ingenix, Jutro Medical, and Quantia. BGK / EIF Institutional LPs Creating the national "Innovate Poland" program to boost CEE competitiveness. PARP (FENG) Grant Provider Funding deep-tech breakthroughs like i4hv's heart valves. Second-Order Implications of AI Dominance The massive integration of AI into Polish startups is no longer just a vertical focus but an infrastructure layer. This transition has several profound effects: Commoditisation of Software Creation: As AI drives the marginal cost of coding toward zero, the "defensible moat" for HealthTech leaders shifts from proprietary software to network effects and unique, high-quality datasets. Agentic AI in Healthcare: We are entering an era of "Agentic AI," where autonomous agents handle supply-side tasks like vetting medical records, scheduling, and brokering, thereby improving platform liquidity and efficiency. The Clinical "GPT Moment": The pharmaceutical industry’s traditional R&D model is being challenged by foundational models that can reason across multiple biological scales, potentially making drug development a predictable engineering task rather than a game of chance. Future Outlook: The Path Toward 2030 The Polish MedTech sector is entering a phase of decentralised growth, with Kraków emerging as a global leader in DeepTech and life sciences while Warsaw remains the financial and software hub. The success of current leaders depends on their ability to navigate the increasingly demanding regulatory environment, particularly CE certification for medical AI and the evolving ISO 13485 standards. Strategic partnerships between startups and traditional IT giants like Asseco Poland, Comarch and Netguru, who remain the top IT partners for the Polish health sector, will be crucial for scaling these innovations into the broader public health system. As these 20 leaders continue to validate their models clinically and commercially, the Polish HealthTech renaissance is poised to redefine not only the domestic medical landscape but also the standards of care across the European and global markets. The transition from "fee-for-service" to "fee-for-health," driven by early detection, personalised simulation, and remote monitoring, represents the ultimate strategic objective for the Polish innovators of 2026 and beyond. Nelson Advisors > European MedTech and HealthTech Investment Banking   Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk Nelson Advisors regularly publish Thought Leadership articles covering market insights, trends, analysis & predictions @  https://www.healthcare.digital     Nelson Advisors publish Europe’s leading HealthTech and MedTech M&A Newsletter every week, subscribe today!  https://lnkd.in/e5hTp_xb    Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk #NelsonAdvisors   #HealthTech   #DigitalHealth   #HealthIT   #Cybersecurity   #HealthcareAI   #ConsumerHealthTech   #Mergers   #Acquisitions   #Partnerships   #Growth   #Strategy   #NHS   #UK   #Europe   #USA   #VentureCapital   #PrivateEquity   #Founders   #SeriesA   #SeriesB   #Founders   #SellSide   #TechAssets   #Fundraising   #BuildBuyPartner   #GoToMarket   #PharmaTech   #BioTech   #Genomics   #MedTech Nelson Advisors LLP   Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Nelson Advisors @ 2026 Events   Digital Health Rewired > March 2026 > Birmingham, UK    NHS ConfedExpo   >  June 2026 > Manchester, UK    HLTH Europe >  June 2026, Amsterdam, Netherlands   HIMSS AI in Healthcare  >  July 2026, New York, USA   Bits & Pretzels >  September 2026, Munich, Germany     World Health Summit 2026  >  October 2026, Berlin, Germany   HealthInvestor Healthcare Summit >  October 2026, London, UK  HLTH USA 2026 >  October 2026, USA   Barclays Health Elevate >  October 2026, London, UK    Web Summit 2026 >  November 2026, Lisbon, Portugal     MEDICA 2026 >  November 2026, Düsseldorf, Germany   Venture Capital World Summit > Toronto, Canada Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk

20 Future Icelandic HealthTech and MedTech Leaders The Icelandic healthcare technology (HealthTech) and medical device (MedTech) sectors have entered a period of unprecedented expansion, transitioning from a localised research infrastructure into a globally competitive innovation hub. This evolution is fundamentally rooted in the unique intersection of Iceland’s high-fidelity genomic data, a single-payer nationalised healthcare system, and a robust academic-clinical nexus centered at the University of Iceland and Landspítali University Hospital. Historically known for pioneering work in population genetics through deCODE genetics, the contemporary Icelandic ecosystem has matured, giving rise to a new generation of leaders who are leveraging artificial intelligence (AI), advanced biotechnology and digital health platforms to address global medical challenges. The emergence of Kerecis as the nation’s first "unicorn", achieving a $1.3 Billion valuation upon its acquisition by Coloplast, serves as a definitive proof-of-concept for the Icelandic model of innovation, catalyzing increased venture capital interest and proving that a small-market environment can produce world-leading medical solutions. The Ecosystem Architecture: Institutional Drivers and Funding Landscapes The trajectory of Icelandic HealthTech is inextricably linked to the institutional support provided by the University of Iceland (UI) and the strategic oversight of Landspítali University Hospital. The rate of innovation has accelerated significantly in recent years, with patent applications from the research community increasing from one per year to nearly one per month by 2024. This productivity is fostered through formalised recognition programs such as the UI Science and Innovation Awards, which provide critical seed funding and institutional validation for projects in health and wellbeing. Strategic Funding and Governance Entity Primary Function in HealthTech Development Key Initiatives and Recent Actions Technology Development Fund (Rannís) National grant provider for early-stage R&D. Awarded ISK 15 million to Kaldur Therapeutics for brain injury research. Frumtak Ventures Leading domestic venture capital firm for HealthTech. Led seed rounds for PLAIO ($4.7M) and Optise ($2.2M). Brunnur Ventures Venture capital firm focusing on global scalability. Early investor in Oculis and contributor to its Nasdaq NY listing. Klak Icelandic Startups Primary business accelerator and mentorship hub. Manages Startup Supernova and facilitates TINC accelerator in Silicon Valley. Kría - New Business Venture Fund Government-backed investment fund. Provided matching fund offers to 11 startups including Kaldur Therapeutics in 2025. The connectivity within the Icelandic startup community, characterised by a "small world" effect where the degree of separation between clinical experts, engineers and investors is minimal, serves as a primary success factor for domestic firms. This proximity allows for rapid prototyping and clinical validation, making Iceland an ideal "test market" for HealthTech products before they scale into the European and United States markets. 1: Guðmundur Fertram Sigurjónsson (Kerecis) - The Regenerative Benchmark Guðmundur Fertram Sigurjónsson, the Founder and CEO of Kerecis, is widely credited with establishing the blueprint for modern Icelandic MedTech success. His innovation, using intact fish skin for tissue regeneration and wound repair, initially faced the challenge of converting a natural byproduct into a high-technology medical product. The Kerecis technology utilizes the biological similarities between fish skin and human skin, providing a scaffold for cell ingrowth that is naturally rich in Omega-3 fatty acids, which reduce inflammation and accelerate healing. Sigurjónsson’s leadership was characterized by an early focus on the United States market, recognizing that the scale required for a MedTech exit could not be achieved domestically. His tenure saw Kerecis grow into a global leader in the wound-care space, culminating in its $1.3 Billion sale to Danish medical giant Coloplast in 2023. Sigurjónsson’s contributions have been recognised with the Asa Gudmundsdottir Wright Award, and he remains a central figure in the newly established Icelandic Academy of Science and Innovation, where he serves as a mentor for the next generation of life science entrepreneurs. 2: Dr. Tryggvi Þorgeirsson (Sidekick Health) - Scaling Digital Therapeutics Sidekick Health, led by CEO and co-founder Dr. Tryggvi Þorgeirsson, represents the pinnacle of the Icelandic digital health sector. The company has developed a patient-centric digital care platform designed to empower individuals with chronic illnesses through behavioural modification and clinical monitoring. Dr. Þorgeirsson, a physician by training, founded the company on the premise that healthcare must move beyond the clinic to manage the daily habits that drive chronic disease outcomes. Sidekick Health has raised over $210 Million to date, positioning it as one of the most well-funded HealthTech companies in the Nordic region. The company’s strategic growth has been marked by high-profile partnerships with five of the world’s twenty largest pharmaceutical companies, integrating digital therapeutics with traditional drug regimens to improve patient adherence and quality of life. Despite maintaining a global presence with offices in Europe and the US, Dr. Þorgeirsson emphasizes that the Icelandic market remains a critical research and development hub due to the country’s high-quality health metrics and collaborative clinical environment. 3: Dr. Hákon Hákonarson (Arctic Therapeutics) - The Genomic Strategist Dr. Hákon Hákonarson is a preeminent figure in the transition of genomic research into clinical applications. As the founder of Arctic Therapeutics (ATx), Hákonarson leverages a career that includes serving as the Chief Scientific Officer of deCODE genetics and founding the Center for Applied Genomics (CAG) at the Children’s Hospital of Philadelphia, the world’s largest pediatric biobank. His expertise is reflected in a scientific output exceeding 1,000 publications, ranking him among the world’s most influential scientific minds. Arctic Therapeutics, established in 2015, uses bioinformatic approaches and AI to repurpose existing drugs and develop new therapies for millions of patients. The company operates a clinical laboratory in Akureyri and maintains commercial operations in Reykjavik and Philadelphia. Hákonarson’s approach minimises the traditional risks of drug development by using genetic data to identify targets with a high probability of clinical success, particularly in the field of rare and hereditary diseases. Leader Key Background and Expertise Primary Organization Leadership Focus Dr. Hákon Hákonarson Former CSO of deCODE; Founder of CAG (CHOP). Arctic Therapeutics Genomic-driven drug repurposing and AI bioinformatics. Ivar Hakonarson Experience in IT startups (Basis, Sensa). Arctic Therapeutics Clinical laboratory operations and commercial growth. Lisa DeMarco 25+ years in pharma (GSK); M&A specialist. Arctic Therapeutics Business development and IP strategy. Dr. Charlly Kao Immunologist; Operational leader at CAG. Arctic Therapeutics Scientific advisement and proof-of-concept design. 4: Dr. Örn Almarsson (Axelyf) - RNA Therapeutics and LNP Platforms In the rapidly evolving field of nucleic acid medicine, Dr. Örn Almarsson, CEO and Co-founder of Axelyf, is positioning Iceland as a center for next-generation drug delivery. Axelyf, founded in 2022, focuses on the development of RNA therapeutics for oncology and autoimmune diseases. The company’s core innovation is its AXL lipid nanoparticle ($LNP$) platform, which was bolstered by the acquisition of assets from 76Bio, Inc., including a library developed by former Moderna mRNA-LNP experts. Dr. Almarsson’s leadership integrates deep expertise in lipid chemistry and delivery biology with AI-driven design to solve the "delivery problem" that has historically limited the efficacy of RNA-based medicines. Axelyf operates as both a platform-enabling collaborator and an internal drug discovery house, with operations spanning Massachusetts and Iceland. The company is supported by a board of directors that includes Árni Blöndal of Brunnur Ventures, reflecting a strong connection to the Icelandic venture ecosystem. 5: Jóhann Guðbjargarson (PLAIO) - Disrupting Pharma Operations with AI Jóhann Guðbjargarson, CEO and Founder of PLAIO, is addressing one of the most persistent inefficiencies in the global pharmaceutical industry: production planning. Despite the high-tech nature of drug manufacturing, many companies still rely on manual spreadsheets for demand and supply planning. PLAIO’s AI-powered software platform, which raised $4.7 Million in seed funding in 2024, digitises these processes to ensure that medicines are delivered to patients on time and with minimal waste. Guðbjargarson’s 25-year career in the software industry, including roles at AGR and Rhino-Aviation, informed his vision for a "Coplanner" AI tool that supports production planners with optimisation suggestions. PLAIO’s platform is currently utilized by prominent European clients such as Coripharma, Camurus, and MS Pharma. Guðbjargarson emphasises that his mission is to "shake up the pharma world" by replacing human-error-prone manual work with precise, predictive technology. 6: Maria Bech (EpiEndo Pharmaceuticals) - Advancing Barrier Science Maria Bech, CEO of EpiEndo Pharmaceuticals, leads a clinical-stage company with a unique focus on the impairment of epithelial barriers as a driver of inflammatory conditions. Bech joined the company in 2021 to guide its transition into clinical development. Under her leadership, EpiEndo has developed "Barriolides," a new class of orally available macrolides that have negligible antimicrobial activity but possess potent anti-inflammatory and immuno-modulatory properties. The company’s lead asset, glasmacinal ($EP395$), is being developed primarily for Chronic Obstructive Pulmonary Disease ($COPD$), which the WHO projects will cost the global economy $4.8$ Trillion by 2030. In early 2026, EpiEndo completed a €9 Million convertible bond issue to fund a larger Phase 2b exacerbation reduction trial, demonstrating consistent investor confidence in Bech’s strategic direction and the potential of barrier-promoting therapies. 7: Dr. Martin Ingi Sigurðsson (Kaldur Therapeutics) - Mitigating Neurological Traumas Kaldur Therapeutics, co-founded in 2024 by Dr. Martin Ingi Sigurðsson, represents a specialised frontier in MedTech: the mitigation of neurological damage caused by cerebral oxygen deprivation. This condition, which occurs during cardiac arrest or oxygen deprivation at birth, currently has limited therapeutic options. Dr. Sigurðsson, who serves as a primary contact for the firm, has overseen its rapid maturation, including the launch of its website in March 2025 and securing significant funding offers from the Icelandic Technology Development Fund and Kría. The startup’s research is based on understanding the molecular mechanisms of hypothermia, a natural protective state against brain injury, to develop new drug derivatives and biomarkers. Kaldur Therapeutics’ potential to significantly reduce the long-term costs and human suffering associated with hypoxic brain injury makes it one of the most high-impact emerging companies in the Icelandic life science landscape. 8: Orri Guðmundsson (NeckCare) - Precision Wearable Diagnostics Orri Guðmundsson, CEO of NeckCare, is leading the commercialisation of sensor technology for cervical spine assessment. NeckCare’s innovation centres on wearable sensors that provide objective analysis of neck mobility and motor control, addressing a significant gap in the diagnosis and treatment of head and neck injuries, including concussions. Under Guðmundsson’s leadership, NeckCare has established the first Cervical Center of Excellence in Iceland and has recently expanded its operations into the United States. The "NeckSmart" technology is used by interdisciplinary teams of healthcare professionals to provide objective data for clinical decision-making, moving beyond the subjective assessments that have traditionally dominated physical therapy and rehabilitation. Guðmundsson’s background in sales and commercial leadership at Airtame and Siteimprove has been instrumental in positioning NeckCare for global market penetration. Leader Core Background Focus Area Technology Application Orri Guðmundsson Financial Economics ($MSc$); Commercial leadership. Cervical Diagnostics Wearable sensors for objective mobility analysis. Adeline Tracz Innovation leader at Landspítali. AI Medical Coding Clinical $NLP$ for multilingual record documentation. Finnur Magnússon Product management (Nox Health, Meniga). Connected Home Care Care coordination platform for aging-in-place. Ólafur Þór Guðbjörnsson Physiotherapist and CEO. Digital Rehabilitation Adaptive home-exercise programs with data-tracking. 9: Adeline Tracz (KatlaCode) - AI-Driven Administrative Efficiency The administrative burden of medical coding is a major source of operational friction in modern hospitals. Adeline Tracz, CEO and Innovation Leader at KatlaCode, is solving this through an AI-powered system specifically designed for Icelandic and Nordic clinical records. KatlaCode, which won the UI Science and Innovation Award in 2024, uses advanced Icelandic language models to assist healthcare professionals in accurate and efficient documentation. The founding team of KatlaCode includes Dr. Arnar Þór Guðjónsson, Head of ENT Surgery, and Dr. Hafsteinn Einarsson, an Associate Professor of Computer Science at the University of Iceland. This multidisciplinary team has already launched a live deployment at Landspítali University Hospital. Tracz’s vision extends beyond Iceland, with a roadmap that includes scaling to other Nordic hospitals and eventually launching multilingual clinical $NLP$ tools for international markets. 10: Dr. Einar Stefánsson (Oculis and Retina Risk) - The Veteran Innovator Dr. Einar Stefánsson is perhaps the most prolific individual innovator in the Icelandic MedTech history, having co-founded at least four biotechnology firms including Oculis, Retina Risk, and Oxymap. Stefánsson, a leading ophthalmologist and professor at the UI Faculty of Medicine, has successfully transitioned from bench research to commercial exits, such as the acquisition of Cyclops ehf. by deCODE genetics in 2000. Oculis, his most prominent venture, has raised over $192 million and is dual-listed on Nasdaq New York and Nasdaq Iceland. The company’s nanoparticle eye drops represent a paradigm shift in ophthalmology, potentially eliminating the need for intravitreal injections to treat retinal diseases. Simultaneously, Stefánsson’s work with Retina Risk provides a digital solution for diabetic patients, using risk calculators to prevent vision loss. His career exemplifies the "physician-entrepreneur" model that is central to the Icelandic innovation ecosystem. 11: Finnur Magnússon ( dala.care ) - Revolutionizing Home Based Care Finnur Magnússon, CEO and Co-founder of dala.care , is addressing the global challenge of aging-in-place through technology-enabled coordination. Founded in early 2023, dala.care is a custom-designed app and platform that connects care recipients, families, and professional caregivers to ensure seamless communication and management of home-based support. Magnússon’s background in product management, including leadership roles at Nox Health and Meniga—informed the intuitive design of the dala.care platform. The project has a deeply personal origin, as Magnússon developed the foundation of the platform while managing care for his father, who lived with Parkinson’s for 13 years. In 2025, dala.care was selected to participate in the TINC business accelerator in Silicon Valley, reflecting its potential for international expansion and its role as a leader in the "connected home care" movement. 12: Brynja Ingadóttir (NúnaTrix) - Gamifying Pediatric Surgery Prep Pediatric surgery is a significant source of trauma for both children and their parents. Brynja Ingadóttir, a co-founder of NúnaTrix, has developed a solution that uses gamification to mitigate this anxiety. Founded in 2019, NúnaTrix creates computer games that prepare children for the surgical experience, helping them understand the process and reducing the fear associated with the clinical environment. The company is part of a broader trend in Iceland of utilizing software to improve patient outcomes through behavioral and psychological interventions. Ingadóttir’s work at NúnaTrix is supported by research conducted at the University of Iceland, highlighting the continued importance of academic spin-offs in the HealthTech sector. 13: Dr. Björn Lárus Örvar (ORF Genetics) - Plant-Based Protein Innovation Dr. Björn Lárus Örvar is a pioneer in "molecular farming," a field that uses plants to produce high-value recombinant proteins. As a co-founder and Chief Scientific Officer of ORF Genetics, Örvar developed a method for growing these proteins inside bioengineered barley plants. This plant-based system is exceptionally pure and safe, making it ideal for use in scientific research and high-end skincare through their BIOEFFECT brand. Founded in 2001, ORF Genetics has raised over $8.2 Million and serves as a model for how Icelandic biotechnology can combine traditional agricultural practices with cutting-edge genetic science. Örvar’s leadership has kept the company at the forefront of the growth factor market, with applications expanding into cellular agriculture and cultured meat production. 14: Kjartan Thorsson (Prescriby) - Data-Driven Opioid Risk Management Kjartan Thorsson, CEO and Co-founder of Prescriby, is a doctor-turned-entrepreneur focusing on the root causes of the opioid crisis. Prescriby is a data-driven platform that helps clinicians manage the tapering of high-risk medications, such as opioids and benzodiazepines, to prevent addiction and ensure safe recovery. Thorsson’s firm secured €2 Million in funding in 2024 to innovate its software, which provides structured recovery plans and objective monitoring for patients. Thorsson advocates for Iceland’s status as a "fantastic test market" for research and development, particularly for public health initiatives that require close collaboration between healthcare providers and technology developers. 15: Dr. Eyþór Rúnar Eiríksson (Euler) - High-Precision MedTech Manufacturing Dr. Eyþór Rúnar Eiríksson, CEO and Co-founder of Euler, is bridging the gap between deep-tech AI and industrial MedTech manufacturing. Euler is a spin-out from the Technical University of Denmark (DTU) but is based in Iceland, and it provides real-time monitoring and fault detection for industrial 3D printing ($LPBF$ and $SLS$ processes). Eiríksson’s leadership has led to a €2 Million seed round in late 2025, co-led by Frumtak Ventures and Kvanted. Euler’s software uses existing printer cameras and AI to identify potential defects during the build process, which is critical for the production of high-stakes medical implants and tools. Eiríksson notes that Euler’s platform can reduce failed builds by 77%, potentially saving $115,000 per printer annually, a crucial advancement for making large-scale 3D printing viable for medical applications. 16: Dr. Jón Jóhannes Jónsson (Lífeind and Parkinson's Test) Dr. Jón Jóhannes Jónsson is a central figure in Icelandic clinical biochemistry and the founder of Lífeind, which specializes in nucleic acid analysis for DNA damage. His leadership in the academic sphere recently culminated in a significant breakthrough: the development of a blood test to diagnose Parkinson’s disease. The project, which won the Health category at the 2025 UI Science and Innovation Awards, uses "Northern Lights analysis" to detect structural defects in mitochondrial genetic material isolated from blood platelets. This innovation offers the potential for early, non-invasive diagnosis of Parkinson’s, which could fundamentally transform how the disease is managed and treated globally. Dr. Jónsson’s ability to bridge university research with clinical practice continues to drive significant advancements in the MedTech space. 17: Guðjón Ólafsson (ProDiGY and Molecular Glues) Guðjón Ólafsson, an Assistant Professor at the UI School of Health Sciences, was the overall winner of the 2025 UI Science and Innovation Prize for the ProDiGY project. ProDiGY (Proximity-driven Discovery of Molecular Glue Targets) uses synthetic human-yeast protein interactions to identify targets for "molecular glues"—a revolutionary class of drugs that help cells eliminate disease-causing proteins . This technology offers a rapid and cost-effective method for cancer drug development, representing the next wave of Icelandic biotech leadership. Ólafsson’s work exemplifies the transition from observational genomics toward functional synthetic biology, providing a new set of tools for the global pharmaceutical industry to address "undruggable" targets. 18: Ólafur Þór Guðbjörnsson (Euneo Health) - Digital Physical Therapy Ólafur Þór Guðbjörnsson is the CEO and a co-founder of Euneo Health, a startup dedicated to making physical therapy more effective through digital tools. Founded in 2021 by a team of physiotherapists, Euneo addresses the problem of low patient adherence to home-exercise programs. The Euneo platform allows clinicians to personalize evidence-based rehabilitation programs and provides real-time data on patient progress. Guðbjörnsson’s leadership has focused on clinical groundedness, ensuring the software meets the actual needs of both therapists and patients. With reports of 73% higher exercise adherence and 93% improved therapy experience from early users, Euneo is a leader in the digital physical therapy space. 19: Sigurður Thorarinsson (Landspítali Innovation) While often working within the institutional framework, Sigurður Thorarinsson, the CTO and Head of Innovation at Landspítali University Hospital, is a pivotal leader in the Icelandic HealthTech ecosystem. Thorarinsson acts as a gatekeeper and facilitator, ensuring that startups have the necessary access to clinical environments for testing and validation. Thorarinsson emphasizes that the small degree of separation between people in Iceland is a key success factor, allowing for agile collaboration between hospital staff and private innovators. His leadership in establishing an innovation path within the hospital has been instrumental in the success of projects like KatlaCode and the specialized one-year program for healthcare professionals focusing on digital technology. 20: Arna Harðardóttir (Helix) - Infrastructure Evolution Arna Harðardóttir, CEO of Helix, manages the digital infrastructure that supports the entire Icelandic healthcare system.Helix originated from a 1993 entrepreneur-led mission to digitise the Icelandic health system and currently services the national Electronic Health Record (EHR) system. Harðardóttir’s leadership is focused on the next evolution of EHRs—moving beyond simple records toward intelligent systems that support the patient journey and provide real-time clinical insights. As a central player in the ecosystem, Harðardóttir ensures that Iceland’s digital foundation remains robust enough to support the advanced AI and diagnostic tools being developed by the startups profiled in this report. Comparative Analysis of Funding and Maturity The Icelandic HealthTech sector is characterised by a high concentration of seed-stage and pre-series A companies, with a few notable mature players (Oculis, Sidekick Health, Alvotech) leading the way. Company Lead Founder/CEO Funding Round Amount Raised Core Industry Sidekick Health Tryggvi Þorgeirsson Late Stage ~$210M Digital Therapeutics Alvotech Management Team Growth/Public Strategic Biosimilars Oculis Einar Stefánsson Nasdaq Public ~$192M Ophthalmology EpiEndo Maria Bech Convertible Bond €9M (2026) Respiratory Biotech PLAIO Jóhann Guðbjargarson Seed $4.7M Pharma Supply Chain Euler Eyþór Rúnar Eiríksson Seed €2M Additive Manufacturing Optise Ómar Thor Ómarsson Pre-Seed $2.2M B2B Marketing/AI Arctic Therapeutics Hákon Hákonarson Undisclosed Biobank Access Genomics Strategic Synthesis: The "Icelandic Model" of Innovation The rise of these 20 leaders suggests several critical success factors that define the Icelandic HealthTech ecosystem: High-Fidelity "Living Lab" Environment : Iceland serves as a unique testbed where startups can achieve 100% market penetration or system-wide clinical validation in a relatively short period. This is particularly evident in the digital health (Sidekick, Helix) and administrative AI (KatlaCode) sectors. Resourceful Biotech : The use of local biological assets—whether it be the genetics of a stable population (Arctic Therapeutics), the bioactive properties of cold-water fish skin (Kerecis, Feel Iceland), or the geothermal potential for high-value algae (Algalif) and barley production (ORF Genetics)—remains a primary differentiator. Cross-Disciplinary Spin-offs : The University of Iceland’s ability to foster collaboration between the School of Health Sciences and the School of Engineering and Natural Sciences has produced a pipeline of companies that are inherently multidisciplinary (Heilsugreind, KatlaCode, Oxymap). Venture Capital Maturation : The presence of sophisticated domestic investors like Frumtak and Brunnur, who understand the specific regulatory and capital requirements of life sciences, allows Icelandic firms to bridge the "valley of death" between university research and international series A rounds. Conclusion: The Global Impact of Icelandic MedTech The future of Icelandic HealthTech is no longer defined by its isolation but by its integration into the global medical landscape. The 20 leaders profiled in this report represent a diverse array of scientific and entrepreneurial talent, ranging from veteran physician-innovators like Dr. Einar Stefánsson to emerging AI specialists like Adeline Tracz and Dr. Eyþór Rúnar Eiríksson. As these companies continue to move through clinical trials and global market expansion, they are likely to achieve significant exits similar to Kerecis, further cementing Iceland’s reputation as a "Life Science Island." The shift from purely observational genomic research toward high-value therapeutics, predictive AI operations, and connected home care reflects a maturing ecosystem that is well-positioned to lead in the age of precision medicine and digital health. For professional peers and global investors, the Icelandic ecosystem offers a high-density cluster of innovation that provides both scientific excellence and a proven path to commercial success. Nelson Advisors > European MedTech and HealthTech Investment Banking   Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk Nelson Advisors regularly publish Thought Leadership articles covering market insights, trends, analysis & predictions @  https://www.healthcare.digital     Nelson Advisors publish Europe’s leading HealthTech and MedTech M&A Newsletter every week, subscribe today!  https://lnkd.in/e5hTp_xb    Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk #NelsonAdvisors   #HealthTech   #DigitalHealth   #HealthIT   #Cybersecurity   #HealthcareAI   #ConsumerHealthTech   #Mergers   #Acquisitions   #Partnerships   #Growth   #Strategy   #NHS   #UK   #Europe   #USA   #VentureCapital   #PrivateEquity   #Founders   #SeriesA   #SeriesB   #Founders   #SellSide   #TechAssets   #Fundraising   #BuildBuyPartner   #GoToMarket   #PharmaTech   #BioTech   #Genomics   #MedTech Nelson Advisors LLP   Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Nelson Advisors @ 2026 Events   Digital Health Rewired > March 2026 > Birmingham, UK    NHS ConfedExpo   >  June 2026 > Manchester, UK    HLTH Europe >  June 2026, Amsterdam, Netherlands   HIMSS AI in Healthcare  >  July 2026, New York, USA   Bits & Pretzels >  September 2026, Munich, Germany     World Health Summit 2026  >  October 2026, Berlin, Germany   HealthInvestor Healthcare Summit >  October 2026, London, UK  HLTH USA 2026 >  October 2026, USA   Barclays Health Elevate >  October 2026, London, UK    Web Summit 2026 >  November 2026, Lisbon, Portugal     MEDICA 2026 >  November 2026, Düsseldorf, Germany   Venture Capital World Summit > December 2026 Toronto, Canada Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk

FemTech startup Daye has been announced as the winner of the Digital Health Rewired Pitchfest 2026 competition following the live final held at Rewired 2026 at the NEC, Birmingham. What Daye does Daye is a women’s health biotech focused on closing the gender health gap through science-led innovation. Its flagship product is the Daye Diagnostic Tampon, which turns a familiar menstrual product into an at-home tool for detecting high‑risk HPV, the leading cause of cervical cancer. About the Pitchfest 2026 win Pitchfest is Digital Health Rewired’s startup competition, offering finalists exposure to NHS digital leaders, investors, and potential NHS pilot partners. For 2026, 16 startups were shortlisted, eight progressed to the live final, and Daye was selected as overall winner after pitching against other digital health innovators such as Astron Health and Cogniss. The winner receives advisory support and the opportunity for a potential NHS pilot with CW+ and Chelsea and Westminster Hospital, giving Daye a route to scale adoption in the NHS. Why judges backed Daye Judges and organisers highlighted Daye’s strong potential to make a real impact in healthcare by reducing barriers to cervical cancer screening through at-home HPV testing. Daye’s founder, Valentina Milanova, framed the solution as a way to turn the UK’s strong science base into delivery at scale, with the aim of contributing to the eradication of cervical cancer and delivering returns both in lives saved and health system savings. Judging Panel Jon Hoeksma, chief executive of Future Health Intelligence Mindy Simon, co-director of NHS Innovation Accelerator Michael Morgan-Curran, chief executive of Asclepius MedTech Limited Lloyd Price, partner at Nelson Advisors Sara Nelson, programme director at DigitalHealth.London Pei-Fen Lin, clinical director of innovation at Moorfields Eye Hospital Chris Sawyer, innovation lead – digital health at Innovate UK The other finalists who competed in the Pitchfest 2026 live final were: Astron Health Cogniss Into-Action.Health , Jigsaw Medical LightHearted AI Mavis Technologies Upskill.Health Source: https://www.digitalhealth.net/2026/03/daye-announced-as-rewired-pitchfest-2026-winner/